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Reagents and solvents were purchased from Sigma-Aldrich or Alfa Aesar and used as received. 1H 
and 13C NMR spectra were obtained with a Brucker-400-MHz instrument (1H at 400 MHz, 13C at 100 
MHz); δ in ppm, J in Hz with TMS as an internal standard. ESIMS: microTOF (BRUKER). Microanalysis: 
Perkin-Elmer 240C analyzer. Column Chromatography was performed using pre-packed column in 
combi flash instrument. Ligands were tested as their hydrochloride salts, prepared by adding 5 
equivalents of HCl (1 N solution in diethyl ether) to a solution of compound in anhydrous methanol. 
All reactions were carried out under an inert atmosphere of nitrogen unless otherwise indicated. All 
compounds were > 95% pure. 
General procedure A:  Grignard addition 
The Grignard reagents were prepared form the corresponding bromides (5 mmol) by reaction with 
magnesium (182 mg, 7.5 mmol) in anhydrous THF (5 ml) containing a crystal of iodine). The Grignard 
reagents were titrated prior to use by adding 1 ml of the Grignard solution to a flask containing 1,10-
phenanthroline (~2 mg) in anhydrous THF (2 ml) (purple solution) and titrating with 1M 2-butanol 
(anhydrous) in THF (end point pale yellow solution)] 
 
A solution of the appropriate Grignard reagent (1 M in THF, 1.2 ml, 1.2 mmol) was treated dropwise 
at room temperature with a solution of N-cyclopropylmethyl-6,14-endo-ethanonorthevinone (8) 
(500 mg, 1.18 mmol) or N-cyclopropylmethyl-6,14-endo-ethanonorthevinal (10) (500 mg, 1.22 
mmol) in anhydrous toluene (12 ml). After stirring at room temperature for 20 h, the reaction was 
quenched by addition of saturated aqueous ammonium chloride solution (20 ml). The phases were 
separated and the aqueous phase extracted with EtOAc. The combined organic phases were washed 
with saturated aqueous sodium bicarbonate, dried over MgSO4, filtered and evaporated in vacuo. 
The residue was purified by column chromatography over silica gel eluting with a gradient from 10% 
to 30% ethyl acetate in hexane. Rf values are recorded from TLC eluted with 30:1:69 ethyl 
acetate/ammonia solution/hexane. 
 
General Procedure B:  3-O-demethylation with propane thiolate and HCl salt formation 
A solution of the appropriate thevinol (0.25 mmol) in anhydrous HMPA (1 ml) under an inert 
atmosphere was treated with sodium hydride (21 mg, 0.875 mmol) followed by 1-propanethiol (79 
µl, 0.875 mmol). After the addition was complete, the reaction mixture was heated to 120°C and 
stirred for 3 h. On cooling to room temperature, NH4Cl (sat, aq) was added and the mixture 
extracted with diethyl ether. The organic extracts were washed with water (3) and brine. The 
organic phase was dried (MgSO4) filtered and evaporated to dryness. The residue was purified by 
column chromatography over silica gel. 
 
The HCl salts were prepared by the addition of 2M HCl in diethyl ether (1.2 equiv.) to a solution of 
the orvinol in diethyl ether. The white precipitate which formed was collected by filtration, washed 
with ether and dried under high vacuum. 
 
General Procedure D: Reduction with LiAlH4 
S3 
 
A solution of the ketone (0.215 mmol) in anhydrous THF (7 ml) was added dropwise to a suspension 
of LiAlH4 (20.5 mg, 0.54 mmol) in THF at room temperature. The resulting mixture was allowed to 
stir for 1 hour and then treated carefully with saturated aqueous sodium sulphate sulphate solution 
until all aluminium salts had precipitated. The aluminium salts were removed by filtration and 
washed with Et2O. The filtrate was dried over MgSO4, evaporated to dryness and the residue purified 
by column chromatography over silica gel (30% ethyl acetate, 0.5% NH4OH in hexane). 
 
General Procedure E:  Swern oxidation 
A solution of DMSO (170 μl, 2.4 mmol) in anhydrous DCM (5 ml) was added dropwise to a solution of 
oxalyl chloride (93 μl, 1.1 mmol) in DCM (2 ml) at -78C. The resulting solution was stirred at -78C 
for 10 min and then treated dropwise with a solution of the alcohol (1 mmol) in DCM (5 ml). The 
reaction was stirred for a further 15 min before triethylamine (0.7 ml, 5 mmol) was added slowly and 
the resulting solution allowed to warm to room temperature. Water (10 ml) was added and the 
resulting mixture stirred for 10 min. The phases were separated and the aqueous phase extracted 
with DCM. The combined organic extracts were washed with saturated ammonium chloride, dried 
over MgSO4, filtered and the solvent removed under reduced pressure. The residue was purified by 
column chromatography over silica gel (0.5% NH4OH, 30% ethyl acetate in hexane) to afford the 
product. 
6,14-endo-ethanonorthevinone hydrochloride (7) (Marton, J.; Simon, C.; Hosztafi, S.; Szabó, Z.; 
Márki, Á.; Borsodi, A.; Makleit, S. New nepenthone and thevinone derivatives. Bioorg. Med. Chem., 
1997, 5, 369-382) 
A solution of 6,14-endo-ethanothevinone (6: 10 g, 26 mmol) in anhydrous acetonitrile (130 ml) was 
treated at room temperature with diisopropyl azodicarboxylate (DIAD, 14 ml, 72 mmol) and the 
resulting mixture brought to reflux and stirred for 3 h. On cooling the acetonitrile was removed 
under reduced pressure and the resulting red/orange oily residue was dissolved in ethanol (84 ml). 
Pyridinium hydrochloride (2.7 g, 23 mmol) was then added and the resulting solution stirred at room 
temperature overnight. The precipitated (7) was collected by filtration, washed with ice-cold ethanol 
and dried under vacuum. A second crop was obtained from the mother liquor after stirring for a 
further 24h. This afforded 8.11 g (7) as a white solid (77%). Mp >300°C (decomp). 1H NMR (270 MHz, 
CDCl3)  0.70 (1H, m), 1.38-1.58 (3H, m), 1.87 (1H, dd, J= 14.0, 3.0 Hz), 2.00 (1H, dd, J=14.0, 5.4 Hz), 
2.20-2.32 (1H, m), 2.25 (3H, s), 2.66-2.76 (1H, m), 2.94-3.13 (3H, m), 3.27-3.41 (2H, m), 3.41 (3H, s), 
3.62 (1H, d, J=6.5 Hz), 3.87 (3H, s), 4.51 (1H, s), 6.66 (1H, d, J=8.5 Hz), 6.77 (1H, d, J=8.5 Hz), 9.17 (1H, 
br s), 10.08 (1H, br d, J=8.6 Hz). 13C NMR (68 MHz, CDCl3)  17.0, 28.2, 29.5, 29.8, 31.0, 34.1, 35.7, 
45.2, 48.7, 52.5, 54.0, 56.8, 76.9, 93.9, 115.2, 120.4, 124.6, 130.0, 142.8, 146.9, 209.6. HRMS (ESI+) 
calcd for C22H28NO4 (MH
+), 370.2018; found 370.2008. 
 
N-cylcopropylmethyl-6,14-endo-ethanonorthevinone (8) 
A solution of 6,14-endo-ethanonorthevinone hydrochloride 7 (6 g, 14.8 mmol) in anhydrous DMF (36 
ml) was treated sequentially at room temperature with sodium bicarbonate (5 g, 60 mmol) and 
(bromomethyl)cyclopropane (1.87 ml, 19.3 mmol). The resulting suspension was heated to 90°C and 
stirred for 20 h. On cooling, the DMF was removed in vacuo and the residue dissolved in water and 
rendered basic with 2 M NaOH solution. The product was extracted into chloroform and the organic 
phases washed with brine, dried over MgSO4, filtered and evaporated to dryness. The resulting 
yellow solid was purified by column chromatography over silica gel (50% ethyl acetate in hexane, 
Rf=0.50) affording 6.15 g 8 as a white solid (98%). Mp 105-106 °C. 
1H NMR (270 MHz, CDCl3)  0.04-
0.10 (2H, m), 0.43-0.49 (2H, m), 0.63-0.80 (1H, m), 1.22-1.34 (1H, m), 1.49-1.75 (4H, m), 1.96-2.08 
(1H, m), 2.20-2.38 (4H, m), 2.25 (3H, s), 2.58-2.77 (2H, m), 2.93-3.11 (3H, m), 3.42 (3H, s), 3.86 (3H, 
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s), 4.47 (1H, s), 6.55 (1H, d, J=8.0 Hz), 6.63 (1H, d, J=8.0 Hz). 13C NMR (68 MHz, CDCl3)  3.4, 4.2, 9.6, 
17.6, 22.8, 28.8, 30.5, 33.9, 35.4, 35.5, 43.8, 46.6, 49.8, 52.4, 56.8, 58.4, 59.9, 77.8, 94.8, 113.9, 
119.2, 128.9, 132.8, 141.8, 146.8, 211.1. HRMS (ESI+) calcd for C26H34NO4 (MH




A mixture of N-cyclopropylmethyl-northebaine (1 equivl) and acrolein (1.2 equiv) in anhydrous 
toluene (4 mL/mmol) was heated at 60°C for 16 h. The solvent and excess acrolein were removed 
under reduced pressure and the residue subjected to column chromatography over silica gel 
(Rf=0.17, 20% EtOAc in hexane). This afforded 15 as a pale yellow solid (96%, α/ mixture ~10:1). 
1H 
NMR (270 MHz, CDCl3)  0.08-0.15 (2H, m), 0.46-0.53 (2H, m), 0.77-0.87 (1H, m), 1.44 (1H, dd, J=13.2 
and 5.5 Hz), 1.83 (1H, dd, J=12.9 and 2.5 Hz), 1.98 (1H, dt, J=12.9 and 5.5 Hz), 2.28-2.46 (2H, m), 
2.67-2.78 (2H, m), 2.97 (1H, dd, J=13.2 and 9.6 Hz), 3.10 (1H, d, J=18.4 Hz), 3.56 (1H, d, J=6.6 Hz), 
3.60 (3H, s), 3.80 (3H, s), 4.62 (1H, d, J=1.1 Hz), 5.58 (1H, d, J=8.8 Hz), 5.88 (1H, d, 8.8 Hz), 6.51 (1H, 
d, J=8.0 Hz), 6.61 (1H, d, J=8.0 Hz), 9.41 (1H, d, J=3.9 Hz). 13C NMR (68 MHz, CDCl3)  3.5, 4.3, 9.6, 
23.3, 26.8, 33.5, 43.0, 44.0, 48.1, 50.0, 56.6, 57.2, 59.9, 81.0, 93.7, 113.4, 119.6, 126.6, 128.2, 134.0, 
137.5, 142.0, 148.0, 20202.0. HRMS (ESI+) calcd for C25H30NO4 (MH
+), 408.2175; found 408.2166. 
N-Cyclopropylmethyl-6,14-endoethanonorthevinal (10) 
A solution of N-cylcopropylmethyl-thevinal (15, ~10:1 :, 11.5 g, 28.3 mmol) in ethanol (230 ml) 
containing 10% palladium on carbon (1.15 g) was vigorously stirred under an atmosphere of 
hydrogen (1 atm) for 3 h. The palladium catalyst was removed by filtration through a plug of celite 
and the solvent removed in vacuo. The residue was subjected to column chromatography over silica 
gel (Rf=0.50, ethyl acetate) affording 10 as an off-white solid. This solid was recrystallised from hot 
ethanol to provide 10 as the pure  isomer (single isomer (), 7.04 g, 61%). 1H NMR (400 MHz, 
CDCl3)  0.06-0.11 (2H, m), 0.44-0.50 (2H, m), 0.70-0.82 (2H, m), 1.08-1.70 (4H, m), 1.90 (1H, dd, 
J=12.4 and 4.4 Hz), 2.02 (1H, dt, J=12.9 and 5.5 Hz), 2.20-2.37 (4H, m), 2.60-2.84 (3H, m), 2.95-3.08 
(2H, m), 3.50 (3H, s), 3.86 (3H, s), 4.58 (1H, d, J=1.9 Hz), 6.57 (1H, d, J=8.0 Hz), 6.70 (1H, d, J=8.0 Hz), 
9.91 (1H, d, J=1.9 Hz). 13C NMR (100.6 MHz, CDCl3)  3.5, 4.2, 9.6, 20.1, 22.8, 26.8, 28.7, 35.4, 35.5, 
43.8, 46.1, 48.8, 56.7, 58.5, 59.9, 77.4, 92.4, 113.8, 119.5, 128.7, 132.4, 141.9, 146.7, 203.5. HRMS 
(ESI+) calcd for C25H32NO4 (MH
+), 410.2326; found 410.2309. 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-methyl-butan-2-ol (9a) 
Using general procedure A, with isopropyl magnesium bromide, 9a was isolated as a white solid (60 
mg, 11%). Rf 0.57. 
1H NMR (270 MHz, CDCl3)  0.07-0.11 (2H, m), 0.44-0.51 (2H, m), 0.69-0.86 (2H, 
m), 0.98 (6H, dd, J=15.7, 6.7 Hz), 1.02-1.12 (1H, m), 1.33 (3H, s), 1.62-2.06 (7H, m), 2.16-2.34 (4H, m), 
2.61 (1H, dd, J=12.0, 5.0 Hz), 2.89-2.74 (1H, m), 2.91 (2H, dd, J=12.4, 6.0 Hz), 3.52 (3H, s), 3.86 (3H, 
s), 4.41 (1H, s), 5.02 (1H, d, J=1.2 Hz), 6.53 (1H, d, J=8.1 Hz), 6.69 (1H, d, J=8.1 Hz). 13C NMR (68 MHz, 
CDCl3)  3.5, 4.2, 9.6, 16.5, 17.3, 18.0, 21.3, 22.7, 30.1, 31.1, 31.4, 34.4, 35.9, 36.0, 43.6, 44.1, 47.0, 
52.8, 56.9, 58.3, 59.8, 80.6, 97.4, 114.0, 119.1, 129.0, 132.8, 141.7, 147.0. HRMS (ESI+) calcd for 
C29H42NO4 (MH
+), 468.3108; found 468.3106 (100%). 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-methyl-pentan-2-ol (9b) 
Using general procedure A, with isobutylyl magnesium bromide, 9b was isolated as a white solid 
(150 mg, 26%). Rf 0.75. 
1H NMR (400 MHz, CDCl3)  0.09-0.11 (2H, m), 0.47-0.50 (2H, m), 0.70-0.84 
(2H, m),0.98-1.07 (2H, m), 0.99 (3H, d, J=6.7 Hz), 1.03 (3H, d, J=6.7 Hz), 1.28-1.43 (1H, m), 1.34 (3H, 
s), 1.65-1.83 (4H, m), 1.86-2.01 (3H, m), 2.19-2.38 (4H, m), 2.63 (1H, dd, J=11.9, 5.0 Hz), 2.78-2.85 
(1H, m), 2.97-3.01 (2H, m), 3.54 (3H, s), 3.87 (3H, s), 4.42 (1H, s), 5.10 (1H, s), 6.54 (1H, d, J=8.1 Hz), 
S5 
 
6.70 (1H, d, J=8.1 Hz). 13C NMR (100.6 MHz, CDCl3)  3.6, 4.2, 9.6, 18.0, 22.8, 23.7, 23.9, 25.3, 25.5, 
30.1, 32.2, 35.9, 36.0, 43.7, 46.7, 47.0, 49.7, 52.9, 57.0, 58.5, 59.9, 76.9, 80.7, 97.2, 114.0, 119.1, 
129.0, 132.8, 141.7, 147.1. HRMS (ESI+) calcd for C30H44NO4 (MH
+), 482.3265; found 482.3271 (100%). 
(2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)-5-methyl-hexan-2-ol (9c) 
Using general procedure A, with isopentyl magnesium bromide, 9c was isolated as a white solid (216 
mg, 37%). Rf 0.71. 
1H NMR (400 MHz, CDCl3)  0.08-0.12 (2H, m), 0.44-0.52 (2H, m), 0.70-0.83 (2H, 
m), 0.91 (3H, d, J=6.4 Hz), 0.93 (3H, d, J=6.8 Hz), 1.01-1.08 (2H, m), 1.19-1.56 (5H, m), 1.34 (3H, s), 
1.66 (1H, dd, J=12.9, 2.4 Hz), 1.74-1.85 (2H, m), 1.90-2.03 (2H, m), 2.19-2.38 (4H, m), 2.64 (1H, dd, 
J=11.9, 4.8 Hz), 2.79-2.86 (1H, m), 2.95-3.01 (2H, m), 3.54 (3H, s), 3.88 (3H, s), 4.42 (1H, s), 5.10 (1H, 
s), 6.54 (1H, d, J=8.1 Hz), 6.70 (1H, d, J=8.1 Hz). 13C NMR (100.6 MHz, CDCl3)  3.6, 4.1, 9.6, 18.0, 22.7, 
22.9, 23.2, 23.8, 28.7, 30.1, 31.8, 31.9, 35.9, 36.0, 39.3, 43.7, 45.8, 47.1, 52.9, 57.0, 58.6, 59.9, 75.8, 
80.6, 97.3, 114.1, 119.2, 129.1, 132.8, 141.7, 147.1. HRMS (ESI+) calcd for C31H46NO4 (MH
+), 
496.3421; found 496.3414 (100%). 
 (1R, 5, 6R, 7R, 14)-1-cyclopentyl-1-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-
cyclopropylmethyl-6,14-ethano-morphinan-7-yl)-ethan-1-ol (9d) 
Using general procedure A, with cyclopentyl magnesium bromide, 9d was isolated as a white solid 
(26 mg, 4.5%). Rf 0.70. 
1H NMR (400 MHz, CDCl3)  0.08-0.12 (2H, m), 0.46-0.53 (2H, m), 0.71-0.90 
(2H, m), 1.01-1.09 (1H, m), 1.16 (1H, dd, J=13.1, 9.5 Hz), 1.36 (3H, s), 1.51-1.83 (11H, m), 1.93-2.00 
(3H, m), 2.19-2.39 (4H, m), 2.64 (1H, dd, J=11.8, 4.9 Hz), 2.81-2.88 (1H, m), 2.97-3.02 (2H, m), 3.54 
(3H, s), 3.88 (3H, s), 4.41 (1H, s), 5.10 (1H, d, J=1.3 Hz), 6.55 (1H, d, J=8.1 Hz), 6.71 (1H, d, J=8.1 Hz). 
13C NMR (100.6 MHz, CDCl3)  3.6, 4.2, 9.6, 18.1, 22.8, 22.8, 25.7, 25.9, 26.0, 26.1, 30.1, 31.8, 35.9, 
36.0, 43.7, 45.4, 47.0, 47.6, 52.9, 57.0, 58.4, 59.9, 76.5, 80.7, 97.3, 114.1, 119.1, 129.1, 132.9, 141.8, 
147.1. HRMS (ESI+) calcd for C31H44NO4 (MH
+), 494.3265; found 494.3258 (100%). 
(2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)-3-cyclopentyl-propan-2-ol (9e) 
Using general procedure A, with cyclopentylmethyl magnesium bromide, 9e was isolated as a white 
solid (260 mg, 43%). Rf 0.70. 
1H NMR (400 MHz, CDCl3)  0.08-0.12 (2H, m), 0.47-0.51 (2H, m), 0.70-
0.84 (2H, m), 1.00-1.08 (2H, m), 1.10-1.21 (2H, m), 1.35 (3H, s), 1.46-1.68 (9H, m), 1.77-1.82 (2H, m), 
1.88-2.03 (4H, m), 2.17-2.30 (3H, m), 2.36-2.40 (1H, m), 2.63 (1H, dd, J=12.0, 5.1 Hz), 2.79-2.86 (1H, 
m), 2.96-3.01 (2H, m), 3.53 (3H, s), 3.87 (3H, s), 4.42 (1H, s), 5.16 (1H, s), 6.54 (1H, d, J=8.1 Hz), 6.65 
(1H, d, J=8.1 Hz). 13C NMR (100.6 MHz, CDCl3)  3.5, 4.2, 9.6, 18.1, 22.8, 23.5, 25.1, 25.3, 30.1, 32.2, 
35.1, 35.4, 35.9, 36.0, 43.8, 46.9, 47.0, 47.3, 52.9, 57.0, 58.4, 59.9, 76.6, 80.7, 97.2, 114.1, 119.1, 
129.0, 132.8, 141.9, 147.1. HRMS (ESI+) calcd for C32H46NO4 (MH
+), 508.3421; found 508.3422 (100%). 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-cyclopentyl-butan-2-ol (9f) 
Using general procedure A with 1-bromo-2-cyclopentyl ethane gave 9f as a white solid (243 mg, 
39%) (Rf=0.76; 0.5% NH4OH, 30% EtOAc in hexane; column ran as a gradient from 10% to 50% EtOAc 
in hexane); 1H NMR (400 MHz, CDCl3)  0.09-0.13 (2H, m), 0.46-0.51 (2H, m), 0.70-0.84 (2H, m), 1.01-
1.18 (4H, m), 1.33 (3H, s), 1.33-1.38 (2H, m), 1.45-1.83 (12H, m), 1.90-2.03 (2H, m), 2.20-2.39 (4H, 
m), 2.64 (1H, dd, J=11.5 and 4.5 Hz), 2.79-2.86 (1H, m), 2.96-3.02 (2H, m), 3.54 (3H, s), 3.88 (3H, s), 
4.42 (1H, s), 5.10 (1H, s), 6.55 (1H, d, J=8.0 Hz), 6.70 (1H, d, J=8.0 Hz). 13C NMR (100.6 MHz, CDCl3)  
3.6, 4.1, 9.6, 18.0, 22.9, 23.7, 25.3, 25.3, 29.2, 30.1, 31.8, 32.8, 33.1, 35.9, 36.0, 40.7, 40.7, 43.7, 45.8, 
47.1, 52.9, 57.0, 58.6, 59.9, 75.8, 80.6, 97.2, 114.1, 119.1, 129.0, 132.8, 141.7, 147.1. HRMS (ESI+) 
calcd for C33H48NO4 (MH
+), 522.3578; found 522.3587 (100%). 




Using general procedure A, with cyclohexyl magnesium bromide, 9g was isolated as a white solid 
(100 mg, 17%). Rf 0.72. 
1H NMR (400 MHz, CDCl3)  0.10-0.13 (2H, m), 0.47-0.51 (2H, m), 0.70-0.85 
(2H, m), 1.00-1.10 (2H, m), 1.16-1.42 (7H, m), 1.34 (3H, s), 1.64-1.88 (9H, m), 1.94 (1H, td, J=12.6, 5.6 
Hz), 2.05 (1H, t, J=10.2 Hz), 2.21-2.33 (2H, m), 2.64 (1H, dd, J=11.9, 5.0 Hz), 2.76-2.83 (1H, m), 2.94-
3.02 (2H, m), 3.53 (3H, s), 3.88 (3H, s), 4.41 (1H, d, J=1.1 Hz), 5.01 (1H, s), 6.55 (1H, d, J=8.1 Hz), 6.71 
(1H, d, J=8.1 Hz). 13C NMR (100.6 MHz, CDCl3)  3.6, 3.9, 9.6, 18.2, 21.0, 22.9, 25.7, 26.6, 26.9, 27.1, 
27.2, 30.1, 31.4, 35.9, 36.0, 43.5, 43.6, 44.8, 46.9, 52.8, 56.9, 58.6, 59.7, 77.3, 80.6, 97.4, 114.0, 
119.1, 129.0, 132.8, 141.6, 146.9. HRMS (ESI+) calcd for C32H46NO4 (MH
+), 508.3421; found 508.3430 
(100%). 
(2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)-3-cyclohexyl-propan-2-ol (9h) 
Using general procedure A, with cyclohexylmethyl magnesium bromide, 9h was isolated as a white 
solid (190 mg, 31%). Rf 0.77. 
1H NMR (400 MHz, CDCl3)  0.10-0.11 (2H, m), 0.48-0.50 (2H, m), 0.70-
0.84 (2H, m), 0.95-1.18 (5H, m), 1.25-1.37 (4H, m), 1.34 (3H, s), 1.54-1.69 (5H, m), 1.78-2.04 (6H, m), 
2.19-2.41 (4H, m), 2.64 (1H, dd, J=12.0, 5.0 Hz), 2.78-2.85 (1H, m), 2.96-3.01 (2H, m), 3.53 (3H, s), 
3.88 (3H, s), 4.43 (1H, s), 5.14 (1H, s), 6.54 (1H, d, J=8.1 Hz), 6.70 (1H, d, J=8.1 Hz). 13C NMR (100.6 
MHz, CDCl3)  3.6, 4.1, 9.6, 18.0, 22.9, 23.5, 26.6, 26.8, 26.9, 30.1, 32.2, 33.0, 35.9, 36.0, 36.1, 36.1, 
43.7, 47.0, 47.2, 48.6, 52.9, 57.0, 58.6, 59.9, 77.0, 80.8, 97.2, 114.0, 119.1, 129.0, 132.8, 141.7, 
147.1. HRMS (ESI+) calcd for C33H48NO4 (MH
+), 522.3578; found 522.3589 (100%). 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-cyclohexyl-butan-2-ol (9i) 
Using general procedure A, with cyclohexylethyl magnesium bromide, 9i was isolated as a white 
solid (223 mg, 35%). Rf 0.74. 
1H NMR (400 MHz, CDCl3)  0.09-0.12 (2H, m), 0.47-0.51 (2H, m), 0.71-
0.82 (2H, m), 0.87-1.07 (3H, m), 1.13-1.53 (9H, m), 1.32 (3H, s), 1.62-1.82 (8H, m), 1.90-2.03 (2H, m), 
2.20-2.39 (4H, m), 2.64 (1H, dd, J=11.9 and 4.9 Hz), 2.79-2.86 (1H, m), 2.95-3.01 (2H, m), 3.54 (3H, s), 
3.88 (3H, s), 4.41 (1H, s), 5.10 (1H, s), 6.54 (1H, d, J=8.1 Hz), 6.70 (1H, d, J=8.1 Hz). 13C NMR (100.6 
MHz, CDCl3)  3.6, 4.1, 9.6, 18.0, 22.9, 23.7, 26.6, 26.6, 26.9, 30.1, 30.3, 31.8, 33.5, 33.9, 35.9, 36.0, 
38.4, 38.8, 43.7, 45.9, 47.1, 52.9, 57.0, 58.6, 59.9, 75.9, 80.6, 97.3, 114.1, 119.1, 129.1, 132.8, 141.7, 
147.1. HRMS (ESI+) calcd for C34H50NO4 (MH
+), 536.3734; found 536.3743 (100%). 
(2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)-3-phenyl-propan-2-ol (9j) 
Using general procedure A, with benzyl magnesium bromide, 9j was isolated as a white solid (400 
mg, 67%). Rf 0.65. 
1H NMR (400 MHz, CDCl3)  0.13-0.17 (2H, m), 0.51-0.56 (2H, m), 0.71-0.79 (1H, 
m), 0.82-0.89 (1H, m), 1.05-1.21 (2H, m), 1.35 (3H, s), 1.57 (1H, dd, J=13.0, 2.5 Hz), 1.73-1.87 (4H, m), 
2.21-2.28 (2H, m), 2.34 (2H, dq, J=12.4, 6.0 Hz), 2.61 (1H, dd, J=11.5, 5.0 Hz), 2.76 (2H, s), 2.97-3.02 
(3H, m), 3.51 (3H, s), 3.87 (3H, s), 4.32 (1H, s), 5.33 (1H, s), 6.55 (1H, d, J=8.2 Hz), 6.70 (1H, d, J=8.2 
Hz), 7.21-7.24 (1H, m), 7.28-7.32 (2H, m), 7.38-7.40 (2H, m). 13C NMR (100.6 MHz, CDCl3)  3.8, 4.0, 
9.7, 18.0, 23.0, 23.1, 30.0, 32.1, 35.7, 36.1, 43.6, 46.2, 47.0, 47.2, 52.9, 56.9, 58.9, 59.9, 76.5, 80.7, 
97.0, 114.0, 119.2, 126.2, 127.7, 129.0, 131.3, 132.8, 137.9, 141.7, 147.1. HRMS (ESI+) calcd for 
C33H42NO4 (MH
+), 516.3108; found 516.3124 (100%). 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-phenyl-butan-2-ol (9k) 
Using general procedure A, with phenethyl magnesium bromide, 9k was isolated as a white solid 
(275 mg, 44%). Rf 0.63. 
1H NMR (400 MHz, CDCl3)  0.09-0.13 (2H, m), 0.47-0.52 (2H, m), 0.73-0.83 
(2H, m), 1.03-1.13 (2H, m), 1.40 (3H, s), 1.65-1.73 (2H, m), 1.76-1.90 (3H, m), 1.94-2.03 (2H, m), 2.20-
2.36 (4H, m), 2.64 (1H, dd, J=12.0 and 4.5 Hz), 2.71-3.02 (5H, m), 3.58 (3H, s), 3.89 (3H, s), 4.44 (1H, d 
J=1.5 Hz), 5.22 (1H, s), 6.56 (1H, d, J=8.3 Hz), 6.71 (1H, d, J=8.3 Hz), 7.16-7.20 (1H, m), 7.26-7.31 (4H, 
m). 13C NMR (100.6 MHz, CDCl3)  3.7, 4.1, 9.6, 17.9, 22.9, 23.6, 29.6, 30.1, 31.8, 35.9, 36.0, 43.6, 
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44.0, 46.0, 47.1, 53.0, 57.0, 58.6, 60.0, 75.7, 80.6, 97.3, 114.1, 119.2, 125.7, 128.5, 128.7, 129.0, 
132.8, 141.7, 143.5, 147.1. HRMS (ESI+) calcd for C34H44NO4 (MH
+), 530.3265; found 530.3275 (100%). 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-methyl-butan-2-ol (1a) 
Using general procedure B with 9a (47 mg) gave 1a as a white solid (45 mg, 99%) (Rf=0.25; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane
1H NMR (400 MHz, CDCl3)  0.09-
0.12 (2H, m), 0,45-0.53 (2H, m), 0.69-0.82 (2H, m), 0.96 (3H, d, J=6.5 Hz), 1.02 (3H, d, J=7.0 Hz), 1.01-
1.12 (2H, m), 1.35 (3H, s), 1.65-2.07 (6H, m), 2.18-2.39 (4H, m), 2.64 (1H, dd, J=12.0 and 5.0 Hz), 
2.80-2.87 (1H, m), 2.95-3.00 (2H, m), 3.52 (3H, s), 4.44 (1H, d, J=1.7 Hz), 4.99 (1H, s), 6.51 (1H, d, 
J=8.0 Hz), 6.69 (1H, d, J=8.0 Hz). 13C NMR (100.6 MHz, CDCl3)  3.6, 4.2, 9.6, 16.5, 17.3, 18.1, 21.4, 
22.9, 30.0, 31.4, 34.5, 35.8, 36.1, 43.7, 44.1, 47.4, 52.8, 58.4, 59.9, 77.2, 80.7, 97.9, 116.4, 119.6, 
128.6, 132.5, 137.3, 145.6. HRMS (ESI+) calcd for C28H40NO4 (MH
+), 454.2952; found 454.2954 (100%).  
Anal. (C28H39NO4.HCl.1.6H2O) C, H, N. 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-methyl-pentan-2-ol (1b) 
Using the general procedure B with 9b (48 mg) gave 1b as a yellow solid (46 mg, 98%) (Rf=0.30; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.06-0.12 (2H, m), 0.45-0.53 (2H, m), 0.69-0.88 (2H, m), 0.98 (3H, d, J=6.5 Hz), 1.02 (3H, d, J=6.5 Hz), 
0.98-1.07 (2H, m), 1.28-1.44 (2H, m), 1.34 (3H, s), 1.66 (1H, dd, J=12.5 and 2.0 Hz), 1.76-1.81 (2H, m), 
1.87-2.04 (3H, m), 2.18-2.38 (4H, m), 2.64 (1H, dd, J=11.5 and 5.0 Hz), 2.79-2.85 (1H, m), 2.95-2.99 
(2H, m), 3.52 (3H, s), 4.43 (1H, s), 5.15 (1H, s), 6.50 (1H, d, J=8.0 Hz), 6.68 (1H, d, J=8.0 Hz). 13C NMR 
(100.6 MHz, CDCl3)  3.6, 4.1, 9.6, 18.0, 22.9, 23.6, 23.9, 25.2, 25.5, 29.9, 32.1, 35.8, 36.1, 43.7, 46.5, 
47.3, 49.6, 52.8, 58.5, 59.9, 77.1, 80.8, 97.5, 116.5, 119.6, 128.3, 132.5, 137.4, 145.7. HRMS (ESI+) 
calcd for C29H42NO4 (MH
+), 468.3108; found 468.3123 (100%).  Anal. (C29H41NO4.HCl.1.5H2O) C, H, N. 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-5-methyl-hexan-2-ol (1c) 
Using the general procedure B with 9c (50 mg) gave 1c as a yellow solid (47 mg, 98%) (Rf=0.26; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.08-0.12 (2H, m), 0.46-0.50 (2H, m), 0.70-0.83 (2H, m), 0.91 (6H, d, J=6.0 Hz), 1.00-1.08 (2H, m), 
1.19-1.26 (1H, m), 1.34 (3H, s), 1.34-1.54 (4H, m), 1.65-1.69 (1H, m), 1.77-1.81 (2H, m), 1.90-2.03 
(2H, m), 2.18-2.38 (4H, m), 2.66 (1H, dd, J=12.0 and 5.0 Hz), 2.79-2.86 (1H, m), 2.95-3.00 (2H, m), 
3.52 (3H, s), 4.42 (1H, s), 5.16 (1H br s), 6.50 (1H, d, J=8.0 Hz), 6.69 (1H, d, J=8.0 Hz). 13C NMR 
(100.6MHz, CDCl3)  3.6, 4.1, 9.6, 18.0, 22.7, 23.0, 23.2, 23.8, 28.7, 30.0, 31.8, 31.8, 35.8, 36.1, 39.2, 
43.7, 45.7, 47.4, 52.9, 58.6, 59.8, 76.1, 80.7, 97.6, 116.5, 119.6, 128.4, 132.5, 137.5, 145.7. HRMS 
(ESI+) calcd for C30H44NO4 (MH
+), 482.3265; found 482.3241 (100%). Anal. (C30H43NO4.HCl.1.5H2O) C, 
H, N. 
 (1R, 5, 6R, 7R, 14)-1-cyclopentyl-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-
cyclopropylmethyl-6,14-ethano-morphinan-7-yl)-ethan-1-ol (1d) 
Using the general procedure above with 9d (47 mg) gave 1d as a yellow solid (40 mg, 83%) (Rf=0.24; 
0.5% NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.08-0.12 (2H, m), 0.45-0.53 (2H, m), 0.69-0.90 (2H, m), 1.00-1.08 (1H, m), 1.16 (1H, dd, J=13.0 and 
9.5 Hz), 1.36 (3H, s), 1.48-1.85 (11H, m), 1.94-2.01 (3H, m), 2.18-2.38 (4H, m), 2.64 (1H, dd, J=12.0 
and 5.0 Hz), 2.81-2.88 (1H, m), 2.95-3.00 (2H, m), 3.52 (3H, s), 4.42 (1H, d, J=1.2 Hz), 5.07 (1H, s), 
6.50 (1H, d, J=8.0 Hz), 6.69 (1H, d, J=8.0 Hz). 13C NMR (100.6 MHz, CDCl3)  3.6, 4.2, 9.6, 18.1, 22.9, 
22.9, 25.7, 25.9, 26.0, 26.1, 30.0, 31.8, 35.8, 36.1, 43.7, 45.4, 47.3, 47.7, 52.8, 58.5, 59.9, 76.7, 80.8, 
97.7, 116.4, 119.6, 128.6, 132.5, 137.3, 145.7. HRMS (ESI+) calcd for C30H42NO4 (MH
+), 480.3114; 
found 480.3097. Anal. (C30H41NO4.HCl.1.5H2O) C, H, N. 
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 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-cyclopentyl-propan-2-ol (1e) 
Using the general procedure above with 9e (50 mg) gave 1e as a yellow solid (46 mg, 93%) (Rf=0.27; 
0.5% NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.08-0.12 (2H, m), 0.47-0.52 (2H, m), 0.69-0.90 (2H, m), 1.00-1.08 (2H, m), 1.13-1.20 (2H, m), 1.35 
(3H, s), 1.46-1.69 (7H, m), 1.76-1.81 (2H, m), 1.85-2.04 (5H, m), 2.18-2.31 (3H, m), 2.36-2.41 (1H, m), 
2.64 (1H, dd, J=12.0 and 5.0 Hz), 2.79-2.86 (1H, m), 2.95-3.00 (2H, m), 3.52 (3H, s), 4.44 (1H, s), 5.14 
(1H, s), 6.50 (1H, d, J=8.0 Hz), 6.69 (1H, d, J=8.0 Hz). 13C NMR (100.6 MHz, CDCl3)  3.6, 4.2, 9.6, 18.1, 
22.9, 23.6, 25.1, 25.3, 30.0, 32.2, 35.1, 35.4, 35.8, 36.1, 43.8, 46.8, 47.2, 47.3, 52.8, 58.4, 59.9, 76.7, 
80.8, 97.6, 116.4, 119.6, 128.5, 132.5, 137.3, 145.6. HRMS (ESI+) calcd for C31H44NO4 (MH
+), 
494.3265; found 494.3262 (100%).  Anal. (C31H43NO4.HCl.1.5H2O) C, H, N. 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-cyclopentyl-butan-2-ol (1f) 
Using the general procedure B with 9f (52 mg) gave 1f as a yellow solid (44 mg, 89%) (Rf=0.27; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.08-0.12 (2H, m), 0.44-0.52 (2H, m), 0.69-0.89 (2H, m), 0.99-1.17 (4H, m), 1.33 (3H, s), 1.33-1.41 
(2H, m), 1.45-1.81 (12H, m), 1.90-2.04 (2H, m), 2.18-2.38 (4H, m), 2.64 (1H, dd, J=11.5 and 5.0 Hz), 
2.79-2.86 (1H, m), 2.95-3.00 (2H, m), 3.52 (3H, s), 4.42 (1H, s), 5.14 (1H, s), 6.51 (1H, d, J=8.0 Hz), 
6.69 (1H, d, J=8.0 Hz). 13C NMR (100.6 MHz, CDCl3)  3.6, 4.1, 9.6, 18.0, 23.0, 23.7, 25.3, 25.3, 29.2, 
30.0, 31.8, 32.8, 33.1, 35.8, 36.1, 40.6, 40.7, 43.7, 45.7, 47.4, 52.8, 58.6, 59.9, 76.0, 80.7, 97.6, 116.5, 
119.6, 128.4, 132.5, 137.4, 145.7. HRMS (ESI+) calcd for C32H46NO4 (MH
+), 508.3421; found 508.3423 
(100%). Anal. (C32H45NO4.HCl.1.5H2O) C, H, N. 
 (1R, 5, 6R, 7R, 14)-1-cyclohexyl-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-
cyclopropylmethyl-6,14-ethano-morphinan-7-yl)-ethan-1-ol (1g) 
Using the general procedure B with 9g (50 mg) gave 1g as a yellow solid (43 mg, 87%) (Rf=0.27; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.09-0.13 (2H, m), 0.46-0.51 (2H, m), 0.68-0.88 (2H, m), 0.99-1.11 (2H, m), 1.19-1.42 (7H, m), 1.34 
(3H, s), 1.64-1.68 (2H, m), 1.74-1.98 (6H, m), 2.03-2.08 (1H, m), 2.19-2.37 (4H, m), 2.65 (1H, dd, 
J=11.5 and 4.5 Hz), 2.76-2.83 (1H, m), 2.94-3.00 (2H, m), 3.51 (3H, s), 4.42 (1H, s), 5.01 (1H, s), 6.50 
(1H, d, J=8.0 Hz), 6.69 (1H, d, J=8.0 Hz). 13C NMR (100.6 MHz, CDCl3)  3.7, 4.0, 9.6, 18.3, 21.1, 23.1, 
25.7, 26.7, 26.9, 27.2, 27.3, 30.0, 31.5, 35.9, 36.2, 43.6, 43.6, 44.9, 47.3, 52.8, 58.7, 59.7, 77.6, 80.7, 
97.8, 116.5, 119.6, 128.5, 132.6, 137.4, 145.7. HRMS (ESI+) calcd for C31H44NO4 (MH
+), 494.3265; 
found 494.3275 (100%). Anal. (C31H43NO4.HCl.1.2H2O) C, H, N. 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-cyclohexyl-propan-2-ol (1h) 
Using general procedure B with 9h (52 mg) gave 1h as a yellow solid (50 mg, 98%) (Rf=0.27; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.08-0.12 (2H, m), 0.45-0.52 (2H, m), 0.68-0.83 (2H, m), 0.94-1.17 (5H, m), 1.24-1.38 (4H, m), 1.34 
(3H, s), 1.54-1.68 (5H, m), 1.76-2.06 (6H, m), 2.18-2.40 (4H, m), 2.64 (1H, dd, J=12.0 and 5.0 Hz), 
2.78-2.85 (1H, m), 2.95-2.99 (2H, m), 3.51 (3H, s), 4.43 (1H, s), 5.19 (1H, s), 6.49 (1H, d, J=8.0 Hz), 
6.68 (1H, d, J=8.0 Hz). 13C NMR (100.6 MHz, CDCl3)  3.6, 4.1, 9.6, 18.0, 22.9, 23.5, 26.6, 26.8, 26.9, 
29.9, 32.1, 33.0, 35.8, 35.9, 36.0, 36.1, 43.7, 47.0, 47.3, 48.4, 52.8, 58.6, 59.8, 77.2, 80.8, 97.5, 116.5, 
119.6, 128.3, 132.5, 137.4, 145.7. HRMS (ESI+) calcd for C32H46NO4 (MH
+), 508.3421; found 508.3418 
(100%). Anal. (C32H45NO4.HCl.H2O) C, H, N. 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-cyclohexyl-butan-2-ol (1i) 
Using the general procedure B with 9i (54 mg) gave 1i as a yellow solid (50 mg, 96%) (Rf=0.26; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
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0.08-0.12 (2H, m), 0.46-0.51 (2H, m), 0.69-1.54 (14H, m), 1.33 (3H, s), 1.62-1.81 (9H, m), 1.90-2.02 
(2H, m), 2.18-2.38 (4H, m), 2.65 (1H, dd, J=12.0 and 5.0 Hz), 2.78-2.85 (1H, m), 2.95-3.00 (2H, m), 
3.52 (3H, s), 4.42 (1H, s), 5.17 (1H, s), 6.50 (1H d, J=8.0 Hz), 6.68 (1H, d, J=8.0 Hz). 13C NMR (100.6 
MHz, CDCl3)  3.6, 4.1, 9.6, 18.0, 22.9, 23.7, 26.6, 26.6, 26.9, 30.0, 30.3, 31.8, 33.5, 33.8, 35.8, 36.1, 
38.3, 38.7, 43.7, 45.7, 47.4, 52.8, 58.6, 59.9, 76.1, 80.7, 97.6, 116.5, 119.6, 128.3, 132.5, 137.5, 
145.7. HRMS (ESI+) calcd for C33H48NO4 (MH
+), 522.3578; found 522.3554 (100%). Anal. 
(C33H47NO4.HCl.1.5H2O) C, H, N. 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-phenyl-propan-2-ol (1j) 
Using the general procedure B with 9j (51 mg) gave 9j as a yellow solid (49 mg, 98%) (Rf=0.21; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.12-0.18 (2H, m), 0.51-0.56 (2H, m), 0.69-0.77 (1H, m), 0.83-0.90 (1H, m), 1.03-1.11 (1H, m), 1.15-
1.21 (1H, m), 1.36 (3H, s), 1.56 (1H, dd, J=13.0 and 2.5 Hz), 1.71-1.85 (4H, m), 2.20-2.39 (4H, m), 2.62 
(1H, dd, J=11.5 and 5.0 Hz), 2.71-2.79 (2H, m), 2.96-3.01 (3H, m), 3.48 (3H, s), 4.32 (1H, s), 5.35 (1H, 
s), 6.50 (1H, d, J=8.0 Hz), 6.69 (1H, d, J=8.0 Hz), 7.20-7.31 (3H, m), 7.38-7.40 (2H, m). 13C NMR (100.6 
MHz, CDCl3)  3.8, 3.9, 9.7, 17.9, 23.0, 23.1, 29.8, 32.0, 35.5, 36.2, 43.6, 45.9, 47.1, 47.2, 52.8, 58.9, 
59.9, 76.7, 80.7, 97.3, 116.5, 119.6, 126.2, 127.7, 128.3, 131.3, 132.4, 137.4, 137.7, 145.7. HRMS 
(ESI+) calcd for C32H40NO4 (MH
+), 502.2952; found 502.2956 (100%). Anal. (C32H39NO4.HCl.2H2O) C, H, 
N. 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-phenyl-butan-2-ol (1k) 
Using the general procedure B with 9k (53 mg) gave 1k as a yellow solid (45 mg, 88%) (Rf=0.2; 0.5% 
NH4OH, 30% EtOAc in hexane; column ran in 30% EtOAc in hexane). 
1H NMR (400 MHz, CDCl3)  
0.06-0.12 (2H, m), 0.46-0.51 (2H, m), 0.70-0.83 (2H, m), 1.01-1.13 (2H, m), 1.40 (3H, s), 1.65-1.83 
(5H, m), 1.93-2.03 (2H, m), 2.18-2.35 (4H, m), 2.64 (1H, dd, J=11.5 and 5.0 Hz), 2.70-3.00 (5H, m), 
3.55 (3H, s), 4.44 (1H, s), 5.25 (1H, s), 6.51 (1H, d, J=8.0 Hz), 6.70 (1H, d, J=8.0 Hz), 7.15-7.19 (1H, m), 
7.24-7.29 (4H, m). 13C NMR (100.6 MHz, CDCl3)  3.7, 4.1, 9.6, 17.9, 22.9, 23.6, 29.6, 30.0, 31.8, 35.8, 
36.1, 43.6, 44.0, 45.9, 47.5, 52.9, 58.6, 60.0, 75.9, 80.7, 97.7, 116.5, 119.7, 125.7, 128.5, 128.7, 
132.5, 137.4, 143.4, 145.7. HRMS (ESI+) calcd for C33H42NO4 (MH
+), 516.3108; found 516.3113 (100%).  
Anal. (C33H41NO4.HCl.2H2O) C, H, N. 
(1l) – known compound, ref  19 
(2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-heptan-2-ol  (1m) 
Using general procedure B with 9m (1.00 g) gave 1m as a white solid (0.63 g, 65%) (Rf 0.55; 10:1 
DCM:MeOH).  1H NMR (270 MHz, CDCl3)  0.10 (2H, m), 0.48 (2H, m), 0.80 (1H, m), 0.90 (3H, t), 1.34 
(3H, s), 2.97 (1H, d), 2.98 (1H, d), 3.53 (3H, s), 4.43 (1H, s), 5.14 (1H, s), 6.50 (1H, d), 6.69 (1H, d); ). 
13C NMR (68 MHz, CDCl3)   3.45, 4.01, 9.46, 14.13, 17.90, 22.28, 22.67, 22.78, 23.50, 29.85, 30.93, 
31.73, 32.47, 35.67, 35.98, 41.38, 43.61, 45.73, 47.26, 52.69, 58.40, 59.80, 75.93, 80.57, 97.51, 
116.39, 119.48, 128.27, 132.39, 137.32, 145.58; HRMS (EI) calcd for C30H43NO4 (M
+) 481.319209; 
found 481.320221 (100%);  Anal. (C30H43NO4.HCl.H2O) C, H, N. 
 
(1n) – Buprenorphine, supplied by the National Institute on Drug Abuse, Bethesda, Maryland. 
 
Series 2 were prepared by reacting 10 with an appropriate Grignard reagent (General Procedure A), 
oxidising the resulting alcohol (General Procedure E) and treating the resulting ketone with methyl 
magnesium bromide (General procedure A).  3-O-demethylation and HCl salt formation were as 




(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)- 2-cyclohexyl-ethan-1-ol (11a: R = cyclohexylmethyl) 
Using general procedure A on 10 with cyclohexylmethylmagnesium bromide gave 11a, isolated as a 
white solid, 89%. 1H NMR (400 MHz, CDCl3)  0.09-0.10 (2H, m), 0.46-0.50 (2H, m), 0.68-0.72 (1H, m), 
0.78-0.89 (3H, m), 0.95-0.98 (1H, m), 1.13-1.28 (5H, m), 1.47-1.53 (4H, m), 1.63-1.71 (8H, m), 1.83-
1.86 (1H, m), 2.00-2.02 (1H, m), 2.21-2.29 (3H, m), 2.58-2.66 (2H, m), 2.95-3.00 (1H, d, J=18.1 Hz), 
3.06-3.08 (1H, d, J=6.3 Hz), 3.41 (1H, s), 3.86 (3H, s), 4.41 (1H, s), 6.53 (1H, d, J=8.1 Hz), 6.68 (1H, d, 
J=8.1 Hz); 13C NMR (100.6 MHz, CDCl3)  3.4, 4.2, 9.3, 20.2, 22.5, 26.1, 26.3, 26.5, 26.7, 29.2, 32.7, 
34.2, 34.3, 35.7, 40.7, 43.6, 43.9, 46.0, 51.1, 56.6, 58.3, 59.8, 66.4, 80.0, 93.3, 113.6, 118.8, 128.6, 
132.8, 141.6, 147.0; HRMS (ESI+) calcd for C32H46NO4 (MH
+), 508.34; found 508.34. 
 
 
(5, 6R, 7R, 14)-1’-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)-2-cyclohexylethanone (12, R = cyclohexylmethyl) 
Using general procedure D on 11a (R = cyclohexylmethyl) gave 12 (R = cyclohexylmethyl) as a white 
solid (80 mg, 32%). 1H NMR (400 MHz, CDCl3)  0.07-0.08 (2H, m), 0.45-0.49 (2H, m), 0.68-0.78 (2H, 
m), 0.84-0.95 (2H, m), 1.12-1.16 (1H, m), 1.22-1.35 (4H, m), 1.50-1.51 (1H, m), 1.54 (3H, s), 1.58-1.68 
(5H, m), 1.83-1.85 (1H, m), 1.90-2.00 (1H, m), 2.26-2.35 (3H, m), 2.37-2.38 (1H, d, J=6.0, Hz), 2.47-
2.53 (1H, dd, J=16.2 Hz, J=8.1 Hz), 2.59-2.63 (1H, m), 2.66-2.73 (1H, m), 2.94-2.99 (2H, m), 3.04-3.06 
(1H, d, J=6.4 Hz), 3.39 (1H, s), 3.86 (3H, s), 4.44 (1H, s), 6.54 (1H, d, J=8.1 Hz), 6.69 (1H, d, J=8.1Hz); 
13C NMR (100.6 MHz, CDCl3)  3.2, 4.0, 9.38, 17.2, 22.6. 26.0, 26.1, 26.2, 28.7, 30.5, 33.0, 33.3, 33.5, 
35.2, 35.4, 43.7, 46.4, 49.3, 52.1, 54.0, 56.7, 58.3, 59.8. 95.1, 114.0, 119.0, 128.8, 132.7, 141.6, 
146.8, 212.7; HRMS (ESI+) calcd for C32H44NO4 (MH
+), 506.33; found 506.33. 
 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-cyclohexyl-propan-2-ol (13: R = cyclohexylmethyl) 
Using procedure A for the addition of methylmagnesium bromide to 12 (R = cyclohexylmethyl), 13 (R 
= cyclohexylmethyl) was isolated as a white solid (34 mg, 89%), 1H NMR (400 MHz, CDCl3)  0.08-0.10 
(2H, m), 0.47-0.50 (2H, m), 0.69-0.72 (2H, m), 0.90-0.99 (2H, m), 1.04-1.10 (2H, m), 1.15 (3H, s), 1.20-
1.28 (3H, m), 1.56-1-68 (8H, m), 1.74-1.77 (2H, m), 1.85 (1H, m), 1.99-2.03 (2H, m), 2.18-2.24 (2H, 
m), 2.26-2.36 (1H, m), 2.58-2.63 (1H, m), 2.78-2.86 (1H, m), 2.96-2.99 (1H, d, J=12.8 Hz), 2.99-2.03 
(1H, d, J=6.0 Hz), 3.51 (1H, s), 3.87 (3H, s), 4.38 (1H, s), 4.68 (1H, s), 6.53 (1H, d, J=8.1 Hz), 6.69 (1H, d, 
J=8.1 Hz); 13C NMR (100.6 MHz, CDCl3)  3.2, 4.1, 9.3, 18.1, 22.5, 25.6, 26.4, 29.4, 32.1, 33.5, 35.4, 
35.6, 35.8, 35.9, 43.4, 43.6, 46.8, 49.6, 52.5, 56.9, 58.1, 59.8, 80.3, 97.1, 114.2, 118.9, 128.9, 132.7, 
141.5, 146.9; HRMS (ESI+) calcd for C33H48NO4 (MH
+), 522.36; found 522.36. 
 
(2S, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-cyclohexyl-propan-2-ol (2e)   
Using General Procedure B on 13 (R = cyclohexylmethyl) gave 2e as a white solid. 1H NMR, 270 MHz 
(CDCl3)  0.07-0.11 (2H, m), 0.46-0.50 (2H, m), 0.67-0.81 (2H, m), 0.86-1.30 (10H, m), 1.55-1.89 (12H, 
m), 1.94-2.08 (2H, m), 2.14-2.26 (3H, m), 2.34-2.41 (1H, m), 2.55 (1H, dd, J=20.50 Hz), 2.76-2.86 (1H, 
m),  2.92 (1H, d, J=18.44 Hz), 2.99 (1H, d, J=6.59 Hz), 3.50 (3H, s), 4.40 (1H, s), 4.71 (1H, s), 6.48 (1H, 
d, J=7.99 Hz), 6.66 (1H, d, J=7.99 Hz); 13C NMR, (CDCl3) δ 3.3, 4.2, 9.3, 18.1, 22.6, 25.5, 26.4, 26.5, 
26.6, 29.9, 32.1, 33.5, 35.4, 35.5, 35.9, 35.9, 43.4, 43.7, 47.2, 49.6, 52.6, 58.1, 59.8, 77.7, 80.5, 97.5, 
116.5, 119.3, 127.9, 132.3, 137.5, 145.6. HRMS, m/z for (C32H46NO4) [MH]
+, calcd- 508.3427, found- 




 (2S, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-methyl-butan-2-ol (2a)     
1H NMR, 270 MHz (CDCl3)  0.05-0.09 (2H, m), 0.46-0.49 (2H, m), 0.64-0.81 (2H, m), 0.96 (3H, d, 
J=6.88 Hz), 1.00 (3H, d, J=6.88 Hz), 1.11-1.21 (5H, m), 1.45 (1H, m), 1.62 (4H, m), 1.93-2.08 (2H, m), 
2.12-2.41 (4H, m), 2.58 (1H, dd, J=4.97 and 11.56 Hz), 2.72-2.81 (1H, m), 2.92 (1H, d, J=17.06 Hz), 
2.99 (1H, d, J=5.78 Hz), 3.48 (3H, s), 3.65-3.72 (1H, bd), 4.42 (1H, s), 6.48 (1H, d, J=7.99 Hz), 6.66 (1H, 
d, J=7.99 Hz); 13C NMR, (CDCl3) δ 3.4, 4.1, 9.4, 18.4, 19.6, 20.3, 22.6, 29.5, 30.6, 34.8, 35.4, 36.1, 43.7, 
46.7, 47.3, 52.2, 58.3, 59.9, 60.4, 78.2, 79.5, 97.1, 116.4, 119.4, 128.2, 132.4, 137.3, 145.6. HRMS, 
m/z for (C28H40NO4) [MH]
+, calcd- 454.2957, found- 454.2944. Anal. (C28H39NO4·HCl·3H2O) C, H, N. 
(2S, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-methyl-pentan-2-ol (2b)    
1H NMR, 270 MHz (CDCl3)  0.07-0.09 (2H, m), 0.46-0.49 (2H, m), 0.68-0.81 (2H, m), 0.91 (3H, d, 
J=6.88 Hz), 0.98-1.08 (6H, m), 1.16 (3H, s), 1.57-1.68 (4H, m), 1.71-1.88 (3H, m), 1.96-2.07 (1H, m), 
2.15-2.29 (3H, m), 2.34-2.41 (1H, m), 2.58 (1H, dd, J=4.67 Hz and 11.56 Hz), 2.75-2.87 (1H, m),  2.93 
(1H, d, J=18.71 Hz), 2.99 (1H, d, J=6.61 Hz), 3.51 (3H, s), 4.40 (1H, s), 4.78 (1H, s), 6.48 (1H, d, J=7.99 
Hz), 6.67 (1H, d, J=7.99 Hz); 13C NMR, (CDCl3) δ 3.3, 4.2, 9.3, 18.1, 22.5, 24.1, 24.6, 25.1, 25.4, 29.8, 
32.1,  35.5, 35.6, 43.7, 44.6, 47.1, 49.7, 52.6, 58.1, 59.8, 77.6, 80.5, 97.4, 116.4, 119.4, 128.1, 132.3, 
137.4, 145.6. HRMS, m/z for (C29H42NO4) [MH]
+, calcd- 468.3114, found- 468.3105. Anal. 
(C29H41NO4·HCl·3H2O) C, H, N. 
 
(2S, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-5-methyl-hexan-2-ol (2c)     
1H NMR, 270 MHz (CDCl3)  0.07-0.09 (2H, m), 0.46-0.50 (2H, m), 0.72-0.81 (2H, m), 0.86-0.94 (6H, 
m), 1.02-1.22 (6H, m), 1.42-1.80 (8H, m), 1.89-2.06 (2H, m), 2.13-2.28 (3H, m), 2.35-2.42 (1H, m), 
2.58 (1H, dd, J=4.94 Hz and 11.56 Hz), 2.76-2.86 (1H, m), 2.93 (1H, d, J=18.71 Hz), 3.00 (1H, d, J=6.88 
Hz), 3.50 (3H, s), 4.42 (1H, s), 4.67 (1H, s), 6.48 (1H, d, J=8.26 Hz), 6.67 (1H, d, J=8.26 Hz); 13C NMR, 
(CDCl3) δ 3.3, 4.2, 9.3, 18.1, 22.5, 23.1, 25.2, 28.8, 29.9, 31.9, 32.5,  34.2, 35.5, 35.9, 43.7, 47.2, 49.1, 
52.6, 58.1, 59.8, 77.4, 80.5, 97.4, 116.5, 119.3, 127.9, 132.3, 137.5, 145.6. HRMS, m/z for (C30H44NO4) 
[MH]+, calcd- 482.3270, found- 482.3268. Anal. (C30H43NO4·HCl·2H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-cyclopentyl-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-
cyclopropylmethyl-6,14-ethano-morphinan-7-yl)-ethan-1-ol (2d)     
1H NMR 400 MHz (CDCl3)  0.07-0.08 (2H, m), 0.44-0.51 (2H, m), 0.70-0.78 (1H, m), 0.79-0.86 (1H, 
m), 1.06-1.20 (5H, m), 1.35-1.58 (6H, m), 1.63-1.81 (6H, m), 1.96-2.03 (2H, m), 2.14-2.47 (4H, m), 
2.60-2.62 (1H, m), 2.73-2.78 (1H, m), 2.94-2.99 (2H, m), 3.51 (3H, s), 4.41 (2H, s), 6.48 (1H, d, J=8.00 
Hz), 6.68 (1H, d, J=8.00 Hz); 13C NMR, (CDCl3) δ 3.4, 4.1, 9.3, 17.8, 21.5, 22.6, 24.3, 26.4, 28.6, 29.4, 
29.7, 30.5, 35.5, 36.1, 43.7, 46.9, 47.4, 48.8, 52.5, 58.3, 59.9, 77.9, 79.9, 97.5, 116.4, 119.4, 128.1, 
132.4, 137.4, 145.6. HRMS, m/z for (C30H42NO4) [MH]
+, calcd- 480.3114, found- 480.3106. Anal. 
(C30H41NO4·HCl·3H2O) C, H, N. 
 
 (2S, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-cyclohexyl-butan-2-ol (2f)    
1H NMR 270 MHz (CDCl3)  0.07-0.09 (2H, m), 0.46-0.50 (2H, m), 0.72-0.93 (4H, m), 1.02-1.28 (10H, 
m), 1.52-1.81 (12H, m), 1.89-2.04 (2H, m), 2.12-2.29 (3H, m), 2.34-2.41 (1H, m), 2.55 (1H, dd, J=20.50 
Hz), 2.77-2.86 (1H, m), 2.93 (1H, d, J=18.71 Hz), 3.00 (1H, d, J=6.59 Hz), 3.49 (3H, s), 4.42 (1H, s), 4.65 
(1H, s), 6.48 (1H, d, J=8.26 Hz), 6.67 (1H, d, J=8.26 Hz); 13C NMR, (CDCl3) δ 3.3, 4.2, 9.4, 18.1, 22.6, 
25.3, 26.4, 26.7, 29.9, 31.2, 31.9, 33.4,  33.7, 33.7, 35.5, 35.9, 38.5, 43.7, 47.2, 49.1, 52.6, 58.1, 59.8, 
76.8, 80.5, 97.5, 116.4, 119.4, 128.1, 132.3, 137.4, 145.6. HRMS, m/z for (C33H48NO4) [MH]
+, calcd- 




 (1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-pentan-2-ol (2g) 
1H NMR (400 MHz, CDCl3)  0.08-0.09 (2H, m), 0.45-0.47 (2H, m), 0.69-0.89 (3H, m), 0.94-0.97 (3H, 
m), 1.1-1.16 (2H, m), 1.24 (2H, s), 1.35-1.46 (2H, m), 1.67-1.71 (4H, m), 1.79-1.88 (2H, m), 2.02-2.07 
(2H, m), 2.16-2.33 (3H, m), 2.46-2.53 (1H, m), 2.61-2.67 (1H, m), 2.84-3.04 (2H, m), 3.33 (3H, s), 4.51 
(1H, s), 5.29 (1H, s), 6.50 (1H, d, J=8.1 Hz), 6.68 (1H, d, J=8.1 Hz); 13C NMR (100.6 MHz, CDCl3)  4.0, 
9.4, 14.7, 16.9, 18.6, 21.2, 25.9, 29.4, 32.6, 35.6, 36.1, 43.4, 45.2, 46.0, 50.5, 52.4, 59.8, 67.0, 70.7, 
88.7, 98.2, 119.4, 120.8, 127.1, 132.3, 137.2, 145.5; HRMS (ESI+) calcd for C28H40NO4 (MH
+), 454.30; 
found 454.31. Anal. (C28H39NO4.HCl.H2O) C, H, N. 
 
 (1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-heptan-2-ol (2h) 
1H NMR (400 MHz, CDCl3)  0.08-0.09 (2H, d, J=4.8 Hz), 0.45-4.48 (2H, m), 0.70-0.79 (2H, m), 0.87-
0.93 (3H, m), 1.06-1.12 (1H, m), 1.31-1.44 (8H, m), 1.67-1.70 (3H, d, J=12.7 Hz), 1.75 (3H, s), 2.02-
2.13 (3H, m), 2.16-2.43 (3H, m), 2.48-2.52 (1H, m), 2.62-2.67 (1H, m), 2.82-2.89 (1H, m), 2.94-2.99 
(1H, d, J=18.4 Hz), 3.00-3.03 (1H, m), 3.33 (3H, s), 3.52 (1H, t, J=12.8 Hz), 4.51 (1H, s), 5.29 (1H, s), 
6.50 (1H, d, J=8.1 Hz), 6.68 (1H, d, J=8.1 Hz); 13C NMR (100.6 MHz, CDCl3)  3.3, 9.4, 14.0, 20.4, 22.3, 
29.5, 31.8, 35.9, 43.8, 46.2, 50.5, 59.8, 67.0, 71.2, 88.7, 98.2, 118.0, 120.8, 127.1, 132.3, 139.0, 
145.9; HRMS (ESI+) calcd for C30H44NO4 (MH
+), 482.33; found 482.35. Anal. (C30H43NO4 HCl.H2O) C, H, 
N. 
 
 (1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3’-dimethylbutan-2-ol (2i) 
1H NMR (400 MHz, MeOD)  0.54-0.59 (2H, d, J=4.8 Hz), 0.82-0.84 (2H, m), 0.87-0.89 (1H, m), 1.10 
(9H, s), 1.15-1.18 (1H, m), 1.34-1.42 (1H, m), 1.52 (3H, s), 1.61-1.69 (1H, m), 1.91-2.02 (2H, m), 2.43-
2.56 (4H, m), 2.96-3.02 (1H, m), 3.07-3.17 (2H, m), 3.32-3.37 (1H, d, J=18.2 Hz), 3.37-3.41 (4H, m), 
3.45 (3H, s), 4.02 (1H, s), 4.71 (1H, s), 6.69 (1H, d, J=8.1 Hz), 6.78 (1H, d, J=8.1 Hz); 13C NMR (100.6 
MHz, MeOD)  3.6, 6.0, 6.9, 20.6, 23.5, 25.5, 27.7, 28.9, 30.9, 32.7, 36.3, 38.7, 41.9, 44.6, 46.8, 59.9, 
61.2, 78.9, 79.1, 92.3, 119.2, 121.1, 132.2, 140.7, 147.4; HRMS (ESI+) calcd for C29H42NO4 (MH
+), 
468.31; found 468.32. Anal. (C29H41NO4.HCl) C, H, N. 
 
Series 3 were prepared by reacting 10 with an appropriate Grignard reagent (General Procedure A), 
oxidising the resulting alcohol (General Procedure E) and treating the resulting ketone with LiAlH4 
(General procedure D).  3-O-demethylation and HCl salt formation were as described in General 
procedure C. This is illustrated in full for R = phenethyl. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)-3-phenyl-propan-1-ol (11a, R = phenethyl) 
Isolated as a white solid 218 mg, 58%). Rf 0.48: 
1H NMR (400 MHz, CDCl3)  0.08-0.10 (2H, m), 0.46-
0.49 (2H, m), 0.72-0.96 (2H, m), 1.15-1.25 (3H, m), 1.51-1.66 (2H, m), 1.72-1.79 (4H, m), 1.90-2.03 
(2H, m), 2.21-2.35 (4H, m), 2.62-2.69 (3H, m), 2.95-3.06 (2H ,dd, J=18.3 Hz, J=6.4 Hz)), 3.38 (3H, s), 
3.86 (3H, s), 4.18 (1H, m), 4.40 (1H, s), 6.53 (1H, d, J=8.0 Hz), 6.68 (1H, d, J=8.0 Hz), 7.16-7.30 (5H, m); 
13C NMR (100.6 MHz, CDCl3)  3.3, 4.0, 9.3, 14.1, 17.8, 21.4, 22.7, 28.5, 31.3, 31.7, 33.4, 35.2, 37.0, 
43.5, 44.1, 45.5, 51.9, 56.9, 56.9, 58.8, 59.8, 93.0, 114.3, 119.0, 125.7, 128.5, 128.6, 133.1, 141.8, 
142.7, 171.0; HRMS (ESI+) calcd for C33H42NO4 (MH
+), 516.31; found 516.31. 
 
(5, 6R, 7R, 14)-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)-3-phenyl-propanone (12: R = phenethyl) 
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11a, R = phenethyl (0.36 mmmol) was treated as described in general procedure E. The residue was 
purified by column chromatography using combi flash machine (30% ethyl acetate in hexane) to 
afford 12 (R = phenethyl). Isolated as a uncoloured solid (100 mg, 54%) Rf 0.55: 1H NMR (400 MHz, 
CDCl3)  0.07-0.09 (2H, d, J=4.9 Hz), 0.44-0.49 (2H, m), 0.73-0.76 (1H, m), 1.15-1.32 (2H, m), 1.53-
1.57 (1H, m), 1.56-1.71 (2H, m), 1.99-2.03 (2H, m), 2.23-2.32 (4H, m), 2.59-2.60 (1H, m), 2.70-2.78 
(2H, m), 2.89-3.08 (5H, m), 3.37 (3H, s), 3.86 (3H, s), 4.43 (1H, s), 6.54 (1H, d, J=8.0 Hz), 6.68 (1H, d, 
J=8.0 Hz), 7.14-7.24 (5H, m); 13C NMR (100.6 MHz, CDCl3)  3.3, 9.4, 17.2, 22.7, 28.6, 29.5, 30.0, 35.2, 
35.4, 43.6, 46.4, 47.7, 49.5, 52.2, 56.7, 58.3, 59.7, 95.1, 114.0, 119.0, 125.7, 128.2, 141.3, 141.7, 
146.7, 211.9; HRMS (ESI+) calcd for C33H40NO4 (MH
+), 514.30; found 514.30. 
 
 (1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-phenyl-propan-1-ol (11b: R = phenethyl) 
12, R = phenethyl (100.0 mg, 0.19 mmol), was treated as described in general procedure D to give 
11b: R = phenethyl.  Isolated as a white solid (86 mg, 86%). Rf 0.51. 
1H NMR (400 MHz, CDCl3)  0.07-
0.09 (2H, m), 0.47-0.49 (2H, m), 0.72-0.80 (2H, m), 0.87-0.99 (2H, m), 1.59-1.82 (5H, m), 1.96-2.04 
(2H, m), 2.18-2.34 (5H, m), 2.61-2.72 (2H, m), 2.74-2.82 (1H, m), 2.92-2.99 (3H, m), 3.54 (3H, s), 3.87 
(3H, s), 4.47-4.48 (1H, d, J=1.8 Hz), 5.46 (1H, s), 6.54 (1H, d, J=8.0 Hz), 6.70 (1H, d, J=8.0 Hz), 7.15-
7.18 (1H, m), 7.24-7.28 (4H, m); 13C NMR (100.6 MHz, CDCl3)  3.5, 3.9, 9.4, 14.1, 17.8, 20.9, 22.6, 
29.2, 31.6, 32.1, 35.1, 36.6, 41.0, 43.4, 45.7, 52.2, 56.7, 58.5, 59.9, 60.2, 73.2, 80.0, 94.4, 114.1, 
119.1, 125.2, 128.2, 128.4, 132.7, 141.7, 142.8, 146.7, 211.905; HRMS (ESI+) calcd for C33H42NO4 
(MH+), 516.31; found 516.31. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-phenyl-propan-1-ol (3i) 
11b: R = phenethyl (54 .0 mg, 0.10 mmol) was treated as described in general procedure B to give 3i. 
Isolated as a white solid (48 mg, 96%). Rf 0.14; 
1H NMR, 270 MHz (CDCl3)  0.06-0.09 (2H, m), 0.45-
0.50 (2H, m), 0.64-0.80 (2H, m), 0.82-0.98 (2H, m), 1.58-1.86 (5H, m), 1.91-2.08 (2H, m), 2.13-2.32 
(4H, m), 2.60-2.84 (3H, m), 2.91-3.03 (3H, m), 3.50 (3H, s), 3.81 (1H, t, J=9.07 Hz), 4.49 (1H, s), 5.45 
(1H, s), 6.48 (1H, d, J=7.99 Hz), 6.67 (1H, d, J=7.99 Hz), 7.13-7.32 (5H, m); 13C NMR, (CDCl3) δ 3.6, 4.1, 
9.5, 18.2, 22.8, 29.2, 31.7, 32.2, 35.2, 35.4, 36.7, 40.7, 43.7, 46.1, 52.2, 58.5, 60.0, 73.5, 76.6, 80.3, 
94.6, 116.7, 119.8, 125.7, 128.4, 128.6, 128.7, 132.5, 137.1, 142.90. HRMS, m/z for (C32H40NO4) 
[MH]+, calcd- 502.2957, found- 502.2956. Anal. (C32H39NO4·HCl·1.5H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-2-methyl-propan-1-ol (3a)     
1H NMR, 270 MHz (CDCl3)  0.05- 0.09 (2H, m), 0.46-0.50 (2H, m), 0.71-0.82 (2H, m), 0.88-0.94 (3H, d, 
J=6.59 Hz), 0.96-1.08 (5H, m), 1.17-1.24 (1H, m), 1.60-1.67 (3H, m), 1.84-1.93 (2H, m), 2.01-2.08 (1H, 
m), 2.14-2.27 (3H, m), 2.29-2.42 (1H, m), 2.63-2.79 (2H, m), 2.92 (1H, d, J=18.44 Hz), 3.49 (3H, s), 
3.69 (1H, d, J=9.91 Hz), 4.51 (1H, s), 5.25 (1H, s),  6.49 (1H, d, J=7.96 Hz), 6.67 (1H, d, J=7.96 Hz); 13C 
NMR (MeOD) δ 3.9, 5.9, 6.8, 14.5, 18.6, 21.1, 25.4, 29.9, 30.3, 31.0, 32.9, 36.7, 38.5, 45.6, 46.8, 52.8, 
60.3 60.7, 78.5, 80.4, 93.7, 119.5, 121.4, 124.3, 131.4, 140.9, 147.4. HRMS, m/z for (C27H38NO4) 
[MH]+, calcd- 440.2801, found- 440.2783. Anal. (C27H37NO4·HCl·2H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-methyl-butan-1-ol (3b)     
1H NMR, 270 MHz (CDCl3)  0.07-0.09 (2H, m), 0.45-0.50 (2H, m), 0.72-1.03 (10H, m), 1.31-1.38 (2H, 
m), 1.5-1.80 (4H, m), 1.92-2.08 (2H, m), 2.13-2.36 (4H, m), 2.61 (1H, dd, J=4.97 and 11.55 Hz), 2.72-
2.82 (1H, m), 2.92-2.99 (2H, m)  3.48 (3H, s), 3.82-3.87 (1H, m), 4.49 (1H, s), 5.34 (1H, s), 6.48 (1H, d, 
J=7.96 Hz), 6.66 (1H, d, J=7.96 Hz); 13C NMR (MeOD) δ 3.9, 5.8, 6.8, 19.3, 21.7, 24.6, 25.3, 30.0, 31.2, 
33.1, 36.8, 41.6, 44.8, 45.7, 46.8, 52.5, 60.3, 60.9, 72.4, 79.8, 93.0, 119.5, 121.3, 124.3, 131.3, 140.9, 
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147.5. HRMS, m/z for (C28H40NO4) [MH]
+, calcd- 454.2957, found- 454.2941. Anal. 
(C28H39NO4·HCl·2H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-methyl-pentan-1-ol (3c)     
1H NMR, 270 MHz (CDCl3)  0.07-0.09 (2H, m), 0.46-0.50 (2H, m), 0.64-0.72 (2H, m), 0.78-0.84 (6H, 
m), 1.24-1.84 (10H, m), 1.99-2.10 (2H, m), 2.16-2.40 (4H, m), 2.61 (1H, dd, J=5.04 and 11.93 Hz), 
2.72-2.85 (1H, m), 2.92-2.99 (2H, m) 3.48 (3H, s), 3.74 (1H, t, J=7.69 Hz), 4.49 (1H, s), 5.37 (1H, s), 
6.48 (1H, d, J=7.96 Hz), 6.66 (1H, d, J=7.96 Hz); 13C NMR, (CDCl3) δ 3.5, 4.4, 9.5, 18.4, 22.5, 22.7, 23.1, 
28.3, 29.3, 32.5, 34.5, 35.2, 35.4, 40.4, 43.8, 46.0, 52.1, 58.4, 60.0, 74.4, 76.6, 80.2, 94.3, 116.7, 
119.7, 128.1, 132.5, 137.5, 145.4. HRMS, m/z for (C29H42NO4) [MH]
+, calcd- 468.3114, found- 
468.3105. Anal. (C29H41NO4·HCl·3H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-cyclopentyl-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-
cyclopropylmethyl-6,14-ethano-morphinan-7-yl)-methanol (3d)     
1H NMR, 270 MHz (CDCl3)  0.07-0.09 (2H, m), 0.46-0.49 (2H, m), 0.68-0.79 (2H, m), 0.96-1.06 (2H, 
m), 1.46-1.80 (12H, m), 1.78-1.90 (1H, m), 1.96-2.04 (1H, m), 2.12-2.25 (4H, m), 2.33-2.41 (1H, m),  
2.60 (1H, dd, J=4.94 and 11.82 Hz), 2.72-2.83 (1H, m),  2.92 (1H, d, J=18.14 Hz), 2.99 (1H, d, J=6.61 
Hz), 3.48 (3H, s), 3.88 (1H, d, J=9.91 Hz), 4.50 (1H, s), 5.28 (1H, s), 6.48 (1H, d, J=7.96 Hz), 6.66 (1H, d, 
J=7.96 Hz); 13C NMR, (CDCl3) δ 3.3, 4.2, 9.2, 18.3, 22.7, 23.9, 26.2, 29.4, 32.2, 33.1, 35.4, 39.2, 41.3, 
43.7, 45.8, 52.2, 58.3, 59.8, 75.5, 80.5, 94.6, 116.5, 119.3, 128.1, 132.3, 137.8, 145.6. HRMS, m/z for 
(C29H40NO4) [MH]
+, calcd- 466.2957, found- 466.2941. Anal. (C29H39NO4·HCl·2H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-cyclohexyl-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-
cyclopropylmethyl-6,14-ethano-morphinan-7-yl)-methanol (3e)     
1H NMR, 270 MHz (CDCl3)  0.05-0.10 (2H, m), 0.47-0.51 (2H, m), 0.66-0.83 (2H, m), 0.92-1.08 (2H, 
m), 1.13-1.33 (4H, m), 1.46-1.69 (7H, m), 1.74-1.83 (2H, m), 1.89-2.10 (3H, m), 2.13-2.30 (3H, m), 
2.35-2.42 (1H, m), 2.61-2.80 (2H, m), 2.92 (1H, d, J=18.71 Hz), 3.00 (1H, d, J=6.61 Hz), 3.47 (3H, s), 
3.64 (1H, d, J=9.91 Hz), 4.51 (1H, s), 5.25 (1H, s), 6.49 (1H, d, J=7.96 Hz), 6.67 (1H, d, J=7.96 Hz); 13C 
NMR (MeOD) δ 3.9, 5.8, 6.8, 18.6, 25.4, 25.7, 27.6, 27.8, 28.0, 30.0, 31.0, 32.1, 32.9, 36.7, 37.6, 39.1, 
40.7, 45.6, 46.8, 52.8, 60.3, 60.8, 78.7, 80.3, 93.6, 119.5, 121.3, 124.3, 131.4, 140.8, 147.4. HRMS, 
m/z for (C30H42NO4) [MH]
+, calcd- 480.3114, found- 480.3096. Anal. (C30H41NO4·HCl·1.5H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-2-cyclohexyl-ethan-1-ol (3f)     
1H NMR, 270 MHz (CDCl3)  0.07-0.09 (2H, m), 0.47-0.50 (2H, m), 0.74-1.08 (6H, m), 1.12-1.45 (6H, 
m), 1.58-1.78 (8H, m), 1.87-2.08 (2H, m), 2.14-2.38 (4H, m), 2.61 (1H, dd, J=4.67 and 11.96 Hz), 2.72-
2.87 (1H, m), 2.92-2.99 (2H, m) 3.48 (3H, s), 3.85 (1H, t, J=9.64 Hz), 4.49 (1H, s), 5.36 (1H, s), 6.48 
(1H, d, J=7.96 Hz), 6.66 (1H, d, J=7.96 Hz); 13C NMR, (CDCl3) δ 3.2, 5.8, 6.1, 18.3, 25.0, 26.3, 26.5, 
26.6, 29.5, 31.5, 32.1, 32.3, 33.6, 34.6, 35.7, 39.5, 42.4, 44.2, 45.9, 51.9, 57.9, 58.9, 71.6, 78.9, 92.0, 
118.5, 120.1, 122.3, 130.2, 139.1, 145.7. HRMS, m/z for (C31H44NO4) [MH]
+, calcd- 494.3270, found- 
494.3253. Anal. (C31H43NO4·HCl·2H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-cyclohexyl-propan-1-ol (3g)    
1H NMR, 270 MHz (CDCl3)  0.06-0.09 (2H, m), 0.46-0.49 (2H, m), 0.64-1.06 (6H, m), 1.12-1.51 (7H, 
m), 1.60-1.80 (10H, m), 1.97-2.08 (1H, m), 2.14-2.39 (4H, m), 2.61 (1H, dd, J=4.94 and 11.56 Hz), 
2.74-2.87 (1H, m), 2.92-2.99 (2H, m)  3.48 (3H, s), 3.69 (1H, t, J=7.96 Hz), 4.49 (1H, s), 5.33 (1H, bd), 
6.48 (1H, d, J=8.26 Hz), 6.66 (1H, d, J=8.26 Hz); 13C NMR, (CDCl3) δ 3.4, 5.7, 6.2, 18.1, 25.1, 26.4, 26.5, 
26.7, 29.6, 31.7, 31.9, 33.1, 33.8, 35.6, 37.5, 39.3, 42.5, 44.3, 46.1, 46.3, 51.7, 52.1, 58.0, 74.3, 78.9, 
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92.3, 118.6, 120.2,  122.2, 130.2, 139.2, 145.7. HRMS, m/z for (C32H46NO4) [MH]
+, calcd- 508.3427, 
found- 508.3433. Anal. (C32H45NO4·HCl·3H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-2-phenyl-ethan-1-ol (3h)     
1H NMR, 270 MHz (CDCl3)  0.09-0.13 (2H, m), 0.48-0.53 (2H, m), 0.73-0.82 (2H, m), 1.02-1.11 (2H, 
m), 1.59-1.66 (3H, m), 1.82-1.88 (1H, m), 1.97-2.09 (1H, m), 2.15-2.41 (4H, m), 2.55-2.69 (2H, m), 
2.90-3.08 (4H, m),  3.44 (3H, s), 4.01 (1H, t, J=7.42 Hz), 4.92 (1H, s), 5.41 (1H, s), 6.50 (1H, d, J=7.99 
Hz), 6.66 (1H, d, J=7.99 Hz), 7.18-7.32 (5H, m); 13C NMR (MeOD) δ 3.9, 5.9, 6.8, 19.4, 25.4, 30.0, 31.6, 
33.0, 36.9, 40.5, 41.7, 45.6, 46.8, 52.4, 60.2, 60.7, 76.0, 79.9, 92.9, 119.5, 121.4, 124.4, 127.2, 129.2, 
130.8, 131.4, 140.4, 140.8, 147.5. HRMS, m/z for (C31H38NO4) [MH]
+, calcd- 488.2801, found- 
488.2807. Anal. (C31H37NO4·HCl·3H2O) C, H, N. 
 
Series 4 were prepared by 3-O-demethylation (General procedure C) of the products from Grignard 
addition to 10.  
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-2-methyl-propan-1-ol (4a)     
1H NMR, 270 MHz (CDCl3)  0.05- 0.09 (2H, m), 0.45-0.49 (2H, m), 0.63-0.65 (1H, m), 0.76-0.82 (1H, 
m), 0.91 (3H, d, J=6.59 Hz), 0.99 (3H, d, J=6.59 Hz), 1.15-1.23 (2H, m), 1.31-1.35 (1H, m), 1.58-1.82 
(4H, m), 1.96-2.08 (2H, m), 2.17-2.29 (3H, m), 2.38-2.47 (1H, m), 2.57-2.62 (2H, m), 2.91 (1H, d, 
J=18.44 Hz), 3.09 (1H, d, J=6.34 Hz), 3.37 (3H, s), 3.66 (1H, d, J=8.83 Hz),  4.47 (1H, d, J=1.64 Hz), 6.47 
(1H, d, J=8.26 Hz), 6.65 (1H, d, J=8.26 Hz); 13C NMR (MeOD) δ 3.8, 6.0, 6.9, 20.1, 20.2, 20.8, 25.4, 
26.1, 29.9, 33.3, 34.2, 37.3, 37.3, 45.8, 46.9, 51.1, 60.1, 61.1, 74.0, 77.2, 91.9, 119.3, 121.1, 124.5, 
131.6, 140.7, 147.8. HRMS, m/z for (C27H38NO4) [MH]
+, calcd- 440.2801, found- 440.2786. Anal. 
(C27H37NO4·HCl·1.5H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopr 
opylmethyl-6,14-ethano-morphinan-7-yl)-3-methyl-butan-1-ol (4b)     
1H NMR, 270 MHz (CDCl3)  0.08- 0.11 (2H, m), 0.47-0.51 (2H, m), 0.63-0.66 (1H, m), 0.78-0.83 (1H, 
m), 0.91-0.95 (6H, m), 1.09-1.22 (2H, m), 1.35-1.42 (1H, m), 1.51-1.58 (2H, m), 1.69-1.78 (4H, m), 
1.98-2.05 (2H, m), 2.19-2.28 (3H, m), 2.37-2.43 (1H, m), 2.60-2.65 (2H, m), 2.91 (1H, d, J=18.18 Hz), 
3.08 (1H, d, J=6.34 Hz), 3.40 (3H, s), 4.17-4.21 (1H, m),  4.43 (1H, d, J=2.21 Hz), 6.47 (1H, d, J=7.96 
Hz), 6.65 (1H, d, J=7.96 Hz); 13C NMR, (CDCl3) δ 3.3, 4.6, 9.4, 20.8, 22.2, 22.7, 23.7, 24.8, 26.7, 29.3, 
35.6, 36.0, 40.0, 44.1, 45.1, 46.3, 50.8, 58.4, 60.0, 66.9, 77.6, 92.5, 116.9, 119.6, 128.1, 132.6, , 137.5, 
145.7. HRMS, m/z for (C28H40NO4) [MH]
+, calcd- 454.2957, found- 454.2931. Anal. 
(C28H39NO4·HCl·2H2O) C, H, N.  
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-4-methyl-pentan-1-ol (4c)     
1H NMR, 270 MHz (CDCl3)  0.05- 0.09 (2H, m), 0.47-0.51 (2H, m), 0.64-0.67 (1H, m), 0.78-0.83 (1H, 
m), 0.88-0.91 (6H, m), 1.13-1.24 (2H, m), 1.28-1.38 (4H, m), 1.48-1.82 (6H, m), 1.98-2.05 (1H, m), 
2.18-2.30 (3H, m), 2.39-2.47 (1H, m), 2.59-2.65 (2H, m), 2.92 (1H, d, J=18.18 Hz), 3.09 (1H, d, J=6.34 
Hz), 3.39 (3H, s), 4.06 (1H, bd),  4.45 (1H, s), 6.49 (1H, d, J=7.99 Hz), 6.66 (1H, d, J=7.99 Hz); 13C NMR, 
(CDCl3) δ 3.3, 4.5, 9.5, 20.8, 22.7, 22.8, 26.6, 28.2, 29.3, 33.9, 35.6, 35.8, 35.9, 39.6, 44.1, 46.3, 50.8, 
52.1, 58.4, 60.0, 69.4, 76.7, 92.5, 116.8, 119.5, 128.1, 132.6, 137.5, 145.7. HRMS, m/z for (C29H42NO4) 
[MH]+, calcd- 468.3114, found- 468.3096. Anal. (C29H41NO4·HCl·2H2O) C, H, N.  
 
(1S, 5, 6R, 7R, 14)-1-cyclopentyl-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-
cyclopropylmethyl-6,14-ethano-morphinan-7-yl)-methanol (4d)      
S16 
 
1H NMR, 270 MHz (CDCl3)  0.05-0.10 (2H, m), 0.45-0.49 (2H, m), 0.61-0.69 (1H, m), 0.76-0.82 (1H, 
m), 1.06-1.22 (3H, m), 1.28-1.43 (2H, m), 1.54-1.78 (7H, m), 1.81-1.91 (3H, m), 1.94-2.05 (2H, m), 
2.12-2.33 (3H, m), 2.41-2.47 (1H, m), 2.44-2.56 (2H, m), 2.92 (1H, d, J=18.44 Hz), 3.13 (1H, bd), 3.38 
(3H, s), 3.79 (1H, d, J=9.91 Hz),  4.46 (1H, d, J=1.65 Hz), 6.48 (1H, d, J=7.99 Hz), 6.66 (1H, d, J=7.99 
Hz); 13C NMR, (CDCl3) δ 3.2, 4.4, 9.4, 21.1, 23.2, 25.4, 25.5, 26.3, 29.3, 29.9, 30.5, 35.7, 35.9, 38.5, 
44.2, 44.9, 46.2, 50.5, 58.2, 59.9, 73.8, 76.8, 92.0, 116.8, 119.5, 128.1, 132.6, 137.5, 145.7. HRMS, 
m/z for (C29H40NO4) [MH]
+, calcd- 466.2957, found- 466.2939. Anal. (C29H39NO4·HCl·0.5H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-2-cyclopentyl-ethan-1-ol (4e)    
1H NMR, 270 MHz (CDCl3)  0.05-0.10 (2H, m), 0.45-0.49 (2H, m), 0.62-0.68 (1H, m), 0.78-0.86 (1H, 
m), 1.06-1.21 (3H, m), 1.31-1.41 (2H, m), 1.45-1.66 (6H, m), 1.72-2.08 (8H, m), 2.18-2.27 (3H, m), 
2.33-2.45 (1H, m), 2.58-2.69 (2H, m), 2.92 (1H, d, J=18.17 Hz), 3.09 (1H, bd), 3.40 (3H, s), 4.13-4.16 
(1H, m),  4.45 (1H, s), 6.48 (1H, d, J=8.26 Hz), 6.66 (1H, d, J=8.26 Hz); 13C NMR, (CDCl3) δ 3.3, 4.4, 9.4, 
20.8, 24.0, 25.1, 25.3, 26.7, 29.4, 32.6, 33.3, 36.0, 36.9, 39.7, 42.4, 44.1, 46.3, 48.4, 50.7, 58.4, 59.9, 
68.3, 76.7, 92.4, 116.8, 119.5, 128.1, 132.6, 137.5, 145.7. HRMS, m/z for (C30H42NO4) [MH]
+, calcd- 
480.3114, found- 480.3086. Anal. (C30H41NO4·HCl·2H2O) C, H, N.  
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-cyclopentyl-propan-1-ol (4f)    
1H NMR, 270 MHz (CDCl3)  0.08-0.10 (2H, m), 0.49-0.52 (2H, m), 0.62-0.68 (1H, m), 0.75-0.86 (1H, 
m), 1.08-1.21 (3H, m), 1.25-1.54 (9H, m), 1.59-1.73 (7H, m), 1.94-2.08 (2H, m), 2.15-2.31 (3H, m), 
2.35-2.47 (1H, m), 2.57-2.69 (2H, m), 2.92 (1H, d, J=18.17 Hz), 3.09 (1H, bd), 3.39 (3H, s), 4.04-4.07 
(1H, m),  4.45 (1H, m), 6.48 (1H, d, J=7.99 Hz), 6.66 (1H, d, J=7.99 Hz); 13C NMR, (CDCl3) δ 3.3, 4.2, 9.4, 
20.7, 21.8, 23.3, 25.3, 25.4, 26.6, 29.3, 31.0, 32.7, 32.9, 33.1, 35.3, 39.7, 40.2, 43.8, 46.3, 50.8, 58.4, 
59.9, 69.4, 77.6, 92.6, 116.8, 119.5, 128.1, 132.6, 137.5, 145.7. HRMS, m/z for (C31H44NO4) [MH]
+, 
calcd- 494.3270, found- 494.3253. Anal. (C31H43NO4·HCl·1.5H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-cyclohexyl-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-
cyclopropylmethyl-6,14-ethano-morphinan-7-yl)-methanol (4g)     
1H NMR, 270 MHz (CDCl3)  0.05-0.11 (2H, m), 0.45-0.49 (2H, m), 0.60-0.65 (1H, m), 0.72-0.82 (1H, 
m), 0.85-0.97 (2H, m), 1.05-1.42 (6H, m), 1.53-1.81 (7H, m), 1.92-2.07 (4H, m), 2.13-2.31 (3H, m), 
2.39-2.46 (1H, m), 2.53-2.67 (2H, m), 2.90 (1H, d, J=18.17 Hz), 3.10 (1H, d, J=6.05 Hz), 3.35 (3H, s), 
3.69 (1H, d, J=8.80 Hz),  4.45 (1H, s), 6.45 (1H, d, J=7.99 Hz), 6.64 (1H, d, J=7.99 Hz); 13C NMR, (CDCl3) 
δ 3.2, 4.1, 9.4, 20.4, 21.4, 26.1, 26.2, 26.3, 26.4, 29.3, 29.8, 29.8, 35.6, 35.9, 41.7, 43.9, 44.2, 46.1, 
50.3, 58.2, 59.9, 73.0, 77.1, 91.8, 116.8, 119.5, 128.1, 132.6, 137.5, 145.7. HRMS, m/z for (C30H42NO4) 
[MH]+, calcd- 480.3114, found- 480.3093. Anal. (C30H41NO4·HCl·1.5H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-2-cyclohexyl-ethan-1-ol (4h)     
1H NMR, 270 MHz (CDCl3)  0.05-0.11 (2H, m), 0.45-0.49 (2H, m), 0.61-0.72 (1H, m), 0.74-1.02 (3H, 
m), 1.11-1.29 (5H, m), 1.33-1.56 (4H, m), 1.61-1.88 (8H, m), 1.96-2.07 (2H, m), 2.15-2.33 (3H, m), 
2.38-2.46 (1H, m), 2.57-2.70 (2H, m), 2.92 (1H, d, J=18.17 Hz), 3.09 (1H, d, J=6.31 Hz), 3.39 (3H, s), 
4.21-4.25 (1H, m),  4.44 (1H, s), 6.48 (1H, d, J=7.96 Hz), 6.66 (1H, d, J=7.96 Hz); 13C NMR, (CDCl3) δ 
3.3, 4.4, 9.4, 20.7, 22.7, 26.3, 26.5, 26.7, 29.3, 29.8, 32.9, 34.2, 34.4, 35.9, 35.9, 40.1, 43.8, 44.1, 46.3, 
50.8, 58.4, 59.9, 66.2, 77.3, 92.6, 116.8, 119.5, 128.1, 132.6, 137.5, 145.7. HRMS, m/z for (C31H44NO4) 
[MH]+, calcd- 494.3270, found- 494.3257. Anal. (C31H43NO4·HCl·2H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-cyclohexyl-propan-1-ol (4i)     
S17 
 
1H NMR, 400 MHz (CDCl3)  0.08-0.11 (2H, m), 0.46-0.51 (2H, m), 0.64-0.68 (1H, m), 0.77-0.82 (1H, 
m), 0.89-0.92 (2H, m), 1.13-1.28 (6H, m), 1.34-1.46 (3H, m), 1.51-1.57 (2H, m), 1.61-1.81 (10H, m), 
2.00 (1H, dt, J=7.04 and 12.64 Hz), 2.20-2.34 (3H, m), 2.37-2.42 (1H, m), 2.61-2.68 (2H, m), 2.94 (1H, 
d, J=18.24 Hz), 3.09 (1H, d, J=6.36 Hz), 3.40 (3H, s), 4.02-4.04 (1H, m),  4.44 (1H, s), 6.49 (1H, d, 
J=8.04 Hz), 6.66 (1H, d, J=8.04 Hz); 13C NMR (MeOD) δ 3.8, 5.9, 6.9, 20.6, 25.4, 26.1, 27.5, 27.6, 27.8, 
30.0, 33.3, 34.5, 34.8, 35.0, 35.2, 37.2, 39.1, 40.3, 45.8, 46.9, 51.2, 60.2, 61.2, 68.8, 77.2, 92.0, 119.4, 
121.1, 124.5, 131.6, 140.7, 147.8. HRMS, m/z for (C32H46NO4) [MH]
+, calcd- 508.3427, found- 
508.3445. Anal. (C32H45NO4·HCl·2H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-2-phenyl-ethan-1-ol (4j) 
1H NMR (400 MHz, CDCl3)  0.11-0.13 (2H, d, J=4.8 Hz), 0.49-0.53 ( 2H, t, J=13.5 Hz), 0.64-0.70 (1H, 
m), 0.76-0.89 (1H, m), 1-14-1.17 (1H, m), 1.22 (1H, s), 1.29-1.43(2H, m), 1.65-1.66 (3H, m), 1.75-1.85 
(3H, m), 1.98-2.05 (1H, m), 2.26-2.33 (2H, m), 2.40-2.45 (1H, dd, J=18.1, 5.4 Hz), 2.63-2.74 (2H, m), 
2.77-2.84 (2H, m), 2.95-3.00 (1H, d, J=18.2 Hz), 3.12-3.13 (1H, d, J=6.4 Hz), 3.28 (1H, s), 4.32-4.34 
(1H, m), 4.40 (1H, s), 6.50 (1H, d, J=8.1 Hz), 6.67 (1H, d, J=8.1 Hz), 7.30 (3H, m), 7.32 (2H, m); 13C 
NMR (100.6 MHz, CDCl3)  3.2, 4.3, 9.4, 20.3, 22.5, 26.1, 29.0, 35.4, 35.8, 38.9, 42.8, 43.9, 46.1, 50.5, 
58.3, 59.8, 69.9, 92.7, 116.3, 119.4, 126.5, 128.6, 129.3, 132.4, 137.1, 138.6, 145.4; HRMS (ESI+) calcd 
for C31H38NO4 (MH
+), 488.28; found 488.29. Anal. (C31H37NO4·HCl·1.5H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-phenyl-propan-1-ol (4k) 
1H NMR (400 MHz, CDCl3)  0.08-0.09 (2H, m), 0.45-0.50 (2H, m), 0.66 (1H, m), 079 (1H, m), 1.12-1.13 
(1H, m), 1.39-1.48 (1H, m), 1.52-1.57 (2H, m), 1.63-1.67 (1H, d, J= 8.0 Hz), 1.70-1.80 (4H, m), 1.90-
1.99 (3H, m), 2.19-2.38 (5H, m), 2.60-2.70 (3H, m), 2.85 (1H, m), 2.93-2.98 (1H, d, J=18.2 Hz), 3.04-
3.05 (1H, d, J=6.3 Hz), 3.35 (3H, s), 4.41 (1H, s), 6.49 (1H, d, J=8.0 Hz), 6.67 (1H, d, J=8.0 Hz),  
7.16 (1H, m), 7.16-7.30 (4H, m); 13C NMR (100.6 MHz, CDCl3)  3.2, 4.1, 9.3, 20.4, 22.6, 26.7, 29.2, 
32.8, 35.5, 35.9, 37.4, 40.2, 43.8, 46.3, 50.8, 58.4, 59.8, 68.9, 93.0, 116.4, 119.4, 125.7,128.3, 132.4, 
137.2, 141.9, 145.5; HRMS (ESI+) calcd for C32H40NO4 (MH
+), 502.30; found 502.30. Anal. 
(C32H39NO4·HCl·0.5H2O) C, H, N. 
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Microanalysis 
Cpd  
C 
Expected 
H 
 
N 
 
C 
Found 
H 
 
N 
1a: C28H39NO4.HCl.1.6H2O 
1b: C29H41NO4.HCl.1.5H2O 
1c: C30H43NO4.HCl.1.5H2O 
1d: C30H41NO4.HCl.1.5H2O 
1e:C31H43NO4.HCl.1.5H2O 
1f: C32H45NO4.HCl.1.5H2O 
1g: C31H43NO4.HCl.2H2O 
1h:C32H45NO4.HCl.H2O 
1i: C33H47NO4.HCl.1.5H2O 
1j: C32H39NO4.HCl.2H2O 
1k: C33H41NO4.HCl.2H2O 
1m: C30H43NO4.HCl.H2O 
2a: C28H39NO4·HCl·3H2O 
2b: C29H41NO4·HCl·3H2O 
2c: C30H43NO4·HCl·2H2O 
2d: C30H41NO4·HCl·3H2O 
2e: C32H45NO4·HCl·1.5H2O 
2f: C33H47NO4·HCl·1.5H2O 
2g: C28H39NO4.HCl.H2O 
2h: C30H43NO4·HCl·H2O 
2i: C29H41NO4.HCl 
3a: C27H37NO4·HCl·2H2O 
3b: C28H39NO4·HCl·2H2O 
3c: C29H41NO4·HCl·3H2O 
3d: C29H39NO4·HCl·2H2O 
3e: C30H41NO4·HCl·1.5H2O 
3f: C31H43NO4·HCl·2H2O 
3g: C32H45NO4·HCl·3H2O 
3h: C31H37NO4·HCl·3H2O 
3i: C32H39NO4·HCl·1.5H2O 
4a: C27H37NO4·HCl·1.5H2O 
4b: C28H39NO4·HCl·2H2O 
4c: C29H41NO4·HCl·2H2O 
4d: C29H39NO4·HCl·0.5H2O 
4e: C30H41NO4·HCl·2H2O 
4f: C31H43NO4·HCl·1.5H2O 
4g: C30H41NO4·HCl·1.5H2O 
4h: C31H43NO4·HCl·2H2O 
4i: C32H45NO4·HCl·2H2O 
4j: C31H37NO4·HCl 
.
1.5H2O 
4k: C32H39NO4·HCl 
.
0.5H2O 
64.8 
65.5 
66.0 
66.3 
66.7 
67.2 
65.8 
68.3 
67.6 
66.9 
67.4 
67.2 
61.8 
62.4 
65.0 
63.2 
67.2 
67.7 
66.2 
67.7 
69.1 
63.3 
63.9 
62.4 
64.7 
66.2 
65.8 
64.2 
64.4 
68.0 
64.4 
63.9 
64.5 
68.1 
65.3 
66.8 
65.3 
65.7 
66.2 
67.5 
70.2 
8.30 
8.47 
8.62 
8.28 
8.43 
8.58 
8.54 
8.61 
8.71 
7.72 
7.88 
8.65 
8.52 
8.67 
8.67 
8.49 
8.58 
8.71 
8.33 
8.65 
8.40 
8.27 
8.43 
8.11 
8.24 
8.29 
8.55 
8.76 
7.67 
7.61 
8.15 
8.43 
8.58 
8.02 
8.40 
8.50 
8.40 
8.55 
8.69 
7.44 
7.49 
2.70 
2.63 
2.57 
2.58 
2.51 
2.45 
2.47 
2.49 
2.39 
2.44 
2.38 
2.61 
2.57 
2.51 
2.53 
2.46 
2.45 
2.39 
2.76 
2.61 
2.78 
2.74 
2.66 
2.47 
2.36 
2.58 
2.47 
2.34 
2.42 
2.48 
2.78 
2.66 
2.59 
2.74 
2.54 
2.51 
2.54 
2.47 
2.41 
2.54 
2.56 
64.5 
65.0 
66.0 
66.1 
66.2 
67.2 
65.6 
67.9 
67.3 
67.1 
66.9 
67.5 
61.3 
61.9 
64.5 
63.7 
66.7 
67.3 
66.4 
67.5 
69.0 
63.6 
63.9 
61.9 
64.6 
65.7 
65.6 
63.8 
64.0 
68.2 
64.2 
63.4 
64.5 
67.7 
64.8 
66.4 
65.4 
65.4 
65.8 
67.1 
70.6 
7.96 
8.22 
8.40 
7.98 
8.19 
8.38 
8.32 
8.32 
8.49 
7.34 
7.47 
8.70 
8.16 
8.23 
8.26 
8.01 
8.41 
8.60 
8.51 
8.72 
8.48 
8.07 
8.38 
8.11 
7.99 
8.29 
8.51 
8.30 
7.35 
7.47 
8.10 
8.03 
8.27 
7.91 
8.10 
8.21 
7.95 
8.22 
8.17 
7.29 
7.40 
2.60 
2.55 
2.53 
2.50 
2.42 
2.37 
2.45 
2.40 
2.35 
2.42 
2.35 
2.37 
2.32 
2.28 
2.47 
2.28 
2.36 
2.27 
2.67 
2.33 
2.53 
2.35 
2.53 
2.47 
2.36 
2.58 
2.25 
2.20 
2.19 
2.28 
2.75 
2.52 
2.57 
2.68 
2.38 
2.44 
2.41 
2.28 
2.30 
2.40 
2.37 
 
